

Consolidated Financial Statements and Supplementary Information

December 31, 2021 and 2020

(With Independent Auditors' Report Thereon)

Table of Contents

	Page
Independent Auditors' Report	1
Consolidated Financial Statements:	
Consolidated Balance Sheets	3
Consolidated Statements of Operations	4
Consolidated Statements of Changes in Net Assets	5
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7
Supplementary Information	
Consolidating Schedule – Balance Sheet Information	42
Consolidating Schedule – Statement of Operations and Changes in Net Assets Information	46



KPMG LLP New Jersey Headquarters 51 John F. Kennedy Parkway Short Hills, NJ 07078-2702

Independent Auditors' Report

The Board of Trustees RWJ Barnabas Health, Inc.:

Opinion

We have audited the consolidated financial statements of RWJ Barnabas Health, Inc. (the Corporation), which comprise the consolidated balance sheets as of December 31, 2021 and 2020, and the related consolidated statements of operations, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Corporation as of December 31, 2021 and 2020, and the results of its operations, the changes in its net assets, and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Corporation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for one year after the date that the consolidated financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.



In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether
 due to fraud or error, and design and perform audit procedures responsive to those risks. Such
 procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the
 consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that
 are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
 effectiveness of the Corporation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that
 raise substantial doubt about the Corporation's ability to continue as a going concern for a reasonable
 period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The consolidating financial statement information is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

KPMG LLP

Short Hills, New Jersey April 27, 2022

Consolidated Balance Sheets

December 31, 2021 and 2020

(In thousands)

Assets	2021	2020
Current assets:		
Cash and cash equivalents \$	154,095	100,380
Short-term investments	755,551	578,074
Assets limited or restricted as to use	90,605	142,603
Patient accounts receivable	678,737	589,224
Estimated amounts due from third-party payors	107,097	31,022
Other current assets	374,803	238,624
Total current assets	2,160,888	1,679,927
Assets limited or restricted as to use, noncurrent portion	819,128	273,902
Investments	4,862,135	5,032,506
Property, plant, and equipment, net	2,910,166	2,563,409
Right-of-use assets	258,089	269,663
Other assets, net	667,089	457,500
Total assets \$ =	11,677,495	10,276,907
Liabilities and Net Assets		
Current liabilities:		
Accounts payable \$	492,231	388,370
Accrued expenses and other current liabilities	1,116,185	949,233
Estimated amounts due to third-party payors	375,500	207,932
Long-term debt	38,468	9,224
Lease obligations	37,942	42,237
Self-insurance liabilities	100,562	82,931
Total current liabilities	2,160,888	1,679,927
Estimated amounts due to third-party payors, net of current portion	62,124	400,550
Self-insurance liabilities, net of current portion	324,618	265,940
Long-term debt, net of current portion	3,327,935	2,592,403
Lease obligations, net of current portion	234,433	237,046
Accrued pension liability	29,018	31,465
Other liabilities	149,930	210,148
Total liabilities	6,288,946	5,417,479
Net assets:		
Without donor restrictions	5,118,887	4,677,376
With donor restrictions	269,662	182,052
Total net assets	5,388,549	4,859,428
Total liabilities and net assets \$ =	11,677,495	10,276,907

Consolidated Statements of Operations

Years ended December 31, 2021 and 2020

(In thousands)

		2021	2020
Revenue:			
Patient service revenue	\$	6,077,874	5,036,674
CARES Act grant revenue		65,110	570,657
Other revenue, net		483,539	293,244
Total revenue	_	6,626,523	5,900,575
Expenses:			
Salaries and wages		2,468,791	2,232,692
Physician fees and salaries		739,895	600,371
Employee benefits		505,911	446,884
Supplies		1,220,247	1,086,619
Other		1,247,553	1,068,852
Interest		100,983	101,203
Depreciation and amortization	_	271,024	257,470
Total expenses	_	6,554,404	5,794,091
Income from operations		72,119	106,484
Nonoperating revenue (expenses):			
Investment income, net		346,699	798,807
Other, net		(1,702)	1,680
Total nonoperating revenue, net		344,997	800,487
Excess of revenue over expenses		417,116	906,971
Other changes:			
Pension changes other than net periodic benefit cost		471	(11,282)
Net assets released from restriction for purchases of property		10 404	10 107
and equipment		19,494	18,107
Other, net	_	4,430	3,792
Increase in net assets without donor restrictions	\$ _	441,511	917,588

Consolidated Statements of Changes in Net Assets

Years ended December 31, 2021 and 2020

(In thousands)

	Without donor restrictions	With donor restrictions	Total net assets
Net assets at December 31, 2019	\$ 3,759,788	173,036	3,932,824
Changes in net assets: Excess of revenue over expenses Pension changes other than net periodic	906,971	_	906,971
benefit cost	(11,282)	_	(11,282)
Change in interest in restricted net assets of unconsolidated foundation	_	(1,817)	(1,817)
Net assets released from restriction Restricted contributions Investment income on restricted investments,	18,107 —	(19,790) 30,321	(1,683) 30,321
net Other	 3,792	491 (189)	491 3,603
Change in net assets	917,588	9,016	926,604
Net assets at December 31, 2020	4,677,376	182,052	4,859,428
Changes in net assets: Excess of revenue over expenses Pension changes other than net periodic	417,116	_	417,116
benefit cost Change in interest in restricted net assets of	471	_	471
unconsolidated foundation Net assets released from restriction Restricted contributions	19,494 —	(1,456) (37,339) 127,042	(1,456) (17,845) 127,042
Investment income on restricted investments, net Other	 4,430	507 (1,144)	507 3,286
Change in net assets	441,511	87,610	529,121
Net assets at December 31, 2021	\$ 5,118,887	269,662	5,388,549

Consolidated Statements of Cash Flows

Years ended December 31, 2021 and 2020

(In thousands)

	20:	21	2020
Cash flows from operating activities:			
Change in net assets	\$ 52	29,121	926,604
Adjustments to reconcile change in net assets to net cash provided by operating activities:		(474)	44.000
Pension changes other than net periodic benefit cost Depreciation and amortization expense	2	(471)	11,282 257,470
Amortization of bond financing costs, premiums, and discounts		71,024 (8,570)	(7,639)
Net change in unrealized losses (gains) on investments		11,113	(561,802)
Realized gains on investments		79,307)	(157,599)
Unrealized gain on interest rate swaps	•	(1,636)	(4,509)
Equity in income of joint ventures		84,396)	(50,967)
Distributions received from investments in joint ventures	· (63,419	43,154
Distributions to noncontrolling interests		358	_
Impairment of goodwill		_	9,314
(Gain) loss on sale of assets		(2,232)	677
Contributions restricted for long-term use	(.	16,756)	(14,544)
Loss on early extinguishment of debt, net		(702)	_
Changes in operating assets and liabilities:	/	00 540)	(25.750)
Patient accounts receivable	,	89,513) 57,877	(35,758) 61,438
Reduction in the carrying amount in the right-of-use assets Other assets		21,892)	(38,852)
Accounts payable, accrued expenses, and other current liabilities	•	54,336	199,989
Estimated amounts due from and to third-party payors		46,933)	535,673
Accrued pension liability		(1,976)	(1,371)
Lease obligation, self-insurance, and other long-term liabilities		37,120)	(34,629)
Net cash provided by operating activities	19	95,744	1,137,931
Cash flows from investing activities:			
Purchases of property, plant, and equipment	•	12,465)	(469,290)
Purchases of investments		21,220)	(7,639,324)
Proceeds from the sale of investments	,	69,873	6,870,462
Investment in joint venture	(18	80,343)	(137,732)
Cash paid in acquisition Proceeds from sale of assets		— 10,580	(1,020) 692
Net cash used in investing activities		33,575)	(1,376,212)
•		30,010)	(1,010,212)
Cash flows from financing activities:			
Proceeds from issuance of debt	87	70,301	_
Borrowings under letter of credit	,,		20,000
Repayments of long-term debt	(;	90,466)	(10,943)
Repayments under letter of credit Payments for deferred financing costs		(5,301)	(20,000)
Distributions to noncontrolling interests		(358)	_
Proceeds from contributions restricted for long-term use		16,756	14,544
Proceeds from conditional grants and contributions for long-term use		2,327	5,958
Net cash provided by financing activities	79	93,259	9,559
Net increase (decrease) in cash and cash equivalents	55	55,428	(228,722)
Cash, cash equivalents, and restricted cash at beginning of year	12	21,565	350,287
Cash, cash equivalents, and restricted cash at end of year	\$6	76,993	121,565
Cash and cash equivalents	\$ 15	54,095	100,380
Restricted cash included in assets limited or restricted as to use	52	22,898	21,185
Total cash, cash equivalents, and restricted cash	\$ 6	76,993	121,565
Supplemental disclosures of cash flow information:	_		
Cash paid for interest	\$	95,360	93,978
Finance lease obligations incurred		2,739	1,169
Supplemental disclosures of noncash investing and financing activities:			
Change in noncash acquisitions of property, plant, and equipment	\$	10,925	63,457

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

(1) Organization

RWJ Barnabas Health, Inc. (the Corporation) is a not for profit, tax-exempt corporation located in West Orange, New Jersey. RWJ Barnabas Health, Inc. is the sole corporate member or sole shareholder of the Corporation's affiliated organizations. The Corporation was organized to develop and operate a multihospital healthcare system providing a comprehensive spectrum of healthcare services, principally to the residents of New Jersey and surrounding areas.

The services and facilities of the Corporation include 11 acute care hospitals, 3 acute care children's hospitals, a pediatric rehabilitation hospital with a network of outpatient centers, a freestanding 100-bed behavioral health center, two trauma centers, a satellite emergency department, ambulatory care centers, geriatric centers, the state's largest behavioral health network, comprehensive home care and hospice programs, fitness and wellness centers, retail pharmacy services, medical groups, multi-site imaging centers, an accountable care organization, a burn treatment facility, comprehensive cancer services, breast centers, and comprehensive cardiac surgery services, including a heart transplant center, a lung transplant center, and kidney transplant centers.

(2) Significant Accounting Policies

(a) Basis of Accounting of Financial Statement Presentation

The consolidated financial statements have been prepared on the accrual basis of accounting and include all affiliates and other entities for which operating control is exercised by the Corporation. Investments in entities where the Corporation does not have operating control are recorded under the equity or cost method of accounting. The Corporation has included its equity share of income or losses from investments in unconsolidated affiliates in other operating revenue. Intercompany balances and transactions are eliminated in consolidation.

(b) Recently Adopted Accounting Pronouncements

The Corporation adopted the Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2018-14, Compensation – Retirement Benefits – Defined Benefit Plans – General (Subtopic 715-20): Disclosure Framework – Changes to the Disclosure Requirements for Defined Benefit Plans for the year ended December 31, 2021. ASU 2018-14 modifies, adds and removes certain disclosure requirements for employers that sponsor defined benefit and other postretirement benefits and has been applied retrospectively.

(c) Use of Estimates

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting year. Actual results could differ from those estimates.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

(d) Cash and Cash Equivalents

Cash and cash equivalents include investments in money market funds and highly liquid debt instruments with original maturities of three months or less, excluding assets limited or restricted as to use.

Cash and cash equivalents are maintained with domestic financial institutions with deposits, which exceed federally insured limits. It is the Corporation's policy to monitor the financial strength of these institutions.

(e) Patient Accounts Receivable

The Corporation has agreements with third-party payors that provide for payment at amounts different from its established charges. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Management regularly reviews accounts and contracts to record explicit price concessions that are netted against patient accounts receivable in the consolidated balance sheets. The Corporation grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor arrangements. The concentration of patient accounts receivable as of December 31, 2021 and 2020 was as follows:

	December 31		
	2021	2020	
Medicare	23 %	23 %	
Medicaid	14	13	
Blue Cross	20	20	
Commercial and managed care	29	31	
Self-pay patients and other	14	13	
	100 %	100 %	

(f) Revenue

(i) Patient Service Revenue

The Corporation's patient service revenue is recognized at the amount that reflects the consideration to which the Corporation expects to be entitled in exchange for providing patient care. These amounts are due from patients and third-party payors and include an estimate of variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Corporation bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility.

Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by the Corporation. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The Corporation believes that this method provides a

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

reasonable representation of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. The Corporation measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Corporation has elected to apply the optional exemption to not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at year-end, which primarily relate to acute care patients (in-house). The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of year-end.

The majority of the Corporation's services are rendered to patients with third-party payor insurance coverage. Reimbursement under these programs for all payors is based on a combination of prospectively determined rates, reimbursed costs, discounted charges, and per diem payments. Amounts received under Medicare and Medicaid programs are subject to review and final determination by program intermediaries or their agents and the contracts the Corporation has with commercial payors also provide for retroactive audit and review of claims. Agreements with third-party payors typically provide for payments at amounts less than established charges. For further discussion on third-party reimbursement, refer to note 5. Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Corporation also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Corporation estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Implicit price concessions are determined based on historical collection experience. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change and are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined. Adjustments arising from a change in the transaction price were not significant for the years ended December 31, 2021 or 2020. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense. There was no bad debt expense for the years ended December 31, 2021 or 2020.

Consistent with the Corporation's mission, care is provided to patients regardless of their ability to pay. The Corporation has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances (e.g., co-pays and deductibles). The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts the Corporation expects to collect based on its collection history with those patients. Patients who meet the Corporation's criteria for charity care are provided care without charge or at amounts less than established charges. The Corporation has determined that it has provided sufficient implicit price concessions for these accounts. Price concessions, including charity care, are not reported as revenue.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

The Corporation has elected the financing component practical expedient and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Corporation's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payors pays for that service will be one year or less. However, the Corporation does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

The Corporation has determined that the nature, amount, timing, and uncertainty of patient service revenue and cash flows are affected by payors and service lines. The following tables reflect patient service revenue from third-party payors, government subsidies, and others (including uninsured patients) for the years ended December 31, 2021 and 2020:

			2021	
		Inpatient	Outpatient	Total
Medicare	\$	1,301,637	715,207	2,016,844
Medicaid		555,847	463,227	1,019,074
Blue Cross		707,139	750,241	1,457,380
Commercial and managed care		654,763	545,376	1,200,139
Self-pay patients and other		144,024	143,018	287,042
State of New Jersey subsidy revenue	_	97,395		97,395
Total patient service				
revenue	\$_	3,460,805	2,617,069	6,077,874

			2020	
	_	Inpatient	Outpatient	Total
Medicare	\$	1,122,101	538,394	1,660,495
Medicaid		499,744	363,005	862,749
Blue Cross		576,847	588,548	1,165,395
Commercial and managed care		596,208	458,167	1,054,375
Self-pay patients and other		124,020	109,064	233,084
State of New Jersey subsidy revenue	_	60,576		60,576
Total patient service				
revenue	\$_	2,979,496	2,057,178	5,036,674

(ii) Other Revenue

Other revenue includes income from grants, equity in the income of healthcare joint ventures, unrestricted contributions, net assets released from restriction for operations, cafeteria sales, and parking. Grant revenue and contributions of the Corporation are nonexchange transactions in

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

which no commensurate value is exchanged. In such cases, contribution accounting is applied under ASC Topic 958-605, *Not-for-Profit Entities, Revenue Recognition*. See note 3 for grant funding received under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. Equity in the income of joint ventures is evaluated under ASC Topic 323, *Investments – Equity Method and Joint Ventures*.

Additionally, pharmacy sales and other contracts related to healthcare services are included in other revenue and consist of contracts, which vary in duration and in performance. Revenue is recognized when the performance obligations identified within the individual contracts are satisfied and collections are probable.

(g) Supplies

Supplies are carried at the lower of cost, determined principally on an average cost basis, or net realizable value. Supplies, totaling \$123,840 and \$126,584, are included in other current assets in the consolidated balance sheets at December 31, 2021 and 2020, respectively.

(h) Assets Limited or Restricted as to Use

Assets limited or restricted as to use include assets held by trustees under bond indenture agreements, assets restricted for self-insurance, assets held for supplemental retirement benefits, and assets restricted by donors for specific purposes or endowment. Amounts required to meet current liabilities of the Corporation are classified as current assets. Restricted cash of \$522,898 and \$21,185 as of December 31, 2021 and 2020, respectively, is included in assets limited or restricted as to use and assets limited or restricted as to use, noncurrent portion, in the consolidated balance sheets. The balance as of December 31, 2021 includes the construction fund from the issuance of the Series 2021A bonds (note 10).

(i) Investments and Investment Income

A significant portion of the Corporation's investments are held in an investment portfolio maintained for the benefit of the Corporation and its affiliates. Debt securities are designated as trading. Investments in equity securities with readily determinable fair values and all investments in debt securities are measured at fair value, based on quoted market prices. Donated investments are recorded at their fair value, based on quoted market prices at the date of receipt.

Alternative investments (nontraditional, not readily marketable asset classes) within the investment portfolio are structured such that the Corporation holds interests in private investment funds, consisting of hedge funds, private equity funds, and real estate funds. These investments are reported at fair value as estimated and reported by general partners, based upon the underlying net asset value (NAV) of the fund or partnership as a practical expedient. Because of inherent uncertainty in these valuations, those estimated values may significantly differ from the values that would have been used had a ready market for the investments existed, and differences could be material.

Investment income not restricted by donors including realized and unrealized gains and losses on investments and changes in the fair value of alternative investments are included in nonoperating

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

revenue. Investment income and realized gains and losses on assets restricted by donors for specific purposes or endowment are included in net assets with donor restrictions.

(j) Property, Plant, and Equipment

Property, plant, and equipment expenditures are recorded at cost or, if donated or impaired, at fair value at the date of donation or impairment. Finance leases are recorded at the present value of the future minimum lease payments at the inception of the lease and are included in property, plant, and equipment.

Depreciation expense is computed on a straight-line basis using estimated useful lives of the assets, ranging from 2 to 40 years. Real estate and equipment held under finance leases and leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the related lease term. Such amortization is included in depreciation expense. Gifts of long-lived assets, such as land, buildings, or equipment, are reported as net assets without donor restrictions, unless explicit donor stipulations specify how the donated assets must be used, and are excluded from the excess of revenue over expenses in the consolidated statements of operations. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as net assets with donor restrictions. Absent explicit stipulations about how long those long-lived assets must be maintained, expirations of donor restrictions are reported when the donated or acquired long-lived assets are placed in service.

(k) Leases

The Corporation determines if an arrangement is a lease at inception. Leases are included in right-of-use (ROU) assets and lease obligations, current and long-term, in the consolidated balance sheets. ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term using the Corporation's incremental borrowing rate. The ROU asset also includes any prepaid rent while excluding lease incentives and initial direct costs incurred.

Lease expense for operating minimum lease payments is recognized on a straight-line basis over the full lease term. Finance leases are included in property, plant, and equipment and long-term debt in the consolidated balance sheets. Finance lease assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term using the explicit interest rate, when available. If an explicit interest rate is not available, the Corporation applies its incremental borrowing rate. Finance lease assets are amortized on a straight-line basis over the full lease term and presented in depreciation and amortization in the consolidated statement of operations. Interest on lease payments is calculated using the effective interest method and presented in interest expense in the consolidated statement of operations.

(I) Deferred Financing Costs

Deferred financing costs represent costs incurred to obtain debt financing arrangements. Amortization of these costs is provided using the effective-interest method over the terms of the applicable indebtedness. Deferred financing costs are presented as a reduction of the related debt.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

During 2021, the Corporation incurred \$5,301 of deferred financing costs related to the issuance of the tax-exempt Series 2021A bonds (note 10). No deferred financing costs were incurred during 2020. In connection with the refunding and refinancing that occurred during 2021, \$416 of unamortized deferred financing costs were written off and are included in nonoperating revenue (expenses) in the accompanying consolidated statement of operations.

(m) Donor-Restricted Gifts

Unconditional promises to give cash and other assets are reported at fair value at the date the promise is received. The gifts are reported as donor-restricted support if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends and/or purpose restriction is accomplished, net assets with donor restrictions are reclassified as net assets without donor restrictions and reported in the consolidated statements of changes in net assets as net assets released from restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as unrestricted contributions in the accompanying consolidated statements of operations.

Pledges receivable represent an unconditional promise to give cash and other assets to the Corporation's affiliates over a period not greater than 20 years. Such amounts are recorded at their present value at the date the promise is received, net of an allowance for uncollectible pledges. Such amounts are included as externally designated or restricted noncurrent assets limited as to use in the consolidated balance sheets.

(n) Net Assets

Resources are classified for reporting purposes as net assets without donor restrictions and net assets with donor restrictions, according to the absence or existence of donor-imposed restrictions. Resources arising from the results of operations or assets set aside by the Board of Trustees are not considered to be donor-restricted. Net assets with donor restrictions represent funds, including contributions and accumulated investment returns, whose use has been restricted by donors to a specific period or purpose or that have been restricted by donors to be maintained in perpetuity to provide a permanent source of income. Generally, the donors of these donor-restricted assets permit the use of part of the income earned on related investments for specific purposes.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

Net assets without and with donor restrictions are available for the following purposes:

	December 31		
	2021	2020	
Without donor restrictions:			
Undesignated	\$ 5,118,887	4,677,376	
With donor restrictions:			
Perpetual in nature	31,346	32,513	
Purpose restricted	159,056	149,232	
Time restricted	 79,260	307	
Net assets	\$ 5,388,549	4,859,428	

(o) Performance Indicator

The consolidated statements of operations include a performance indicator, which is the excess of revenue over expenses. Changes in net assets without donor restrictions, which are excluded from excess of revenue over expenses, include certain changes in pension obligations, capital contributions, and other transactions.

The Corporation differentiates its ongoing operating activities by providing income from operations as a sub performance indicator. Investment income, net, net periodic benefit costs other than service costs, interest rate swap mark-to-market adjustments, gain on early extinguishment of debt, and other transactions, which are not considered to be components of the Corporation's ongoing activities, are excluded from income from operations and reported as nonoperating revenue in the consolidated statements of operations. Investment income earned on assets limited as to use under bond indenture agreements is included in other revenue in the consolidated statements of operations.

(p) Income Taxes

The Corporation and its affiliates, excluding its for-profit subsidiaries and nominee owned captive professional medical services corporation, are not-for-profit corporations and are exempt from federal and state income taxes on related income under existing provisions of the Internal Revenue Code and State of New Jersey statutes.

The Corporation's for-profit subsidiaries have recorded various deferred income tax assets and liabilities that reflect temporary differences between the amounts of assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes. These amounts, where applicable, to the Corporation are included as other assets or other liabilities in the consolidated balance sheets as appropriate. In addition, the provision for income taxes recorded by the Corporation's for-profit subsidiaries, where applicable, have been made for in the consolidated results of operations of the Corporation and is included in other expenses in the consolidated statement of operations.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

Certain for-profit subsidiaries have federal net operating loss (NOL) carryforwards of approximately \$26,268 that expire through 2037 and State of New Jersey NOL carryforwards of approximately \$59,334 that also expire through 2041. Certain for-profit subsidiaries have federal NOL carryforwards of approximately \$32,512 that expire indefinitely. At December 31, 2021 and 2020, all deferred tax assets related to these NOL carryforwards have been fully reserved due to the uncertainty of realizing the tax benefits associated with these amounts.

The Corporation and its affiliates recognize the financial statements effects of tax positions when they are more likely than not, based on technical merits, that the positions will be sustained upon examination by the tax authorities. Benefits from tax positions that meet the more-likely-than-not recognition threshold are measured at the largest amount of benefit that is greater than 50% likely of being realized upon settlement. The Corporation does not have any significant uncertain tax positions as of December 31, 2021 and 2020.

(q) Self-Insurance

Under the Corporation's self-insurance programs, claims are recorded based upon actuarial estimation, including both reported and incurred but not reported claims, taking into consideration the severity of incidents and the expected timing of claim payments (note 13a, b, and c).

(r) Impairment of Long-Lived Assets

Management routinely evaluates the carrying value of its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of assets, or a related group of assets, may not be recoverable from estimated undiscounted cash flows generated by the underlying tangible assets. When the carrying value of an asset exceeds its estimated recoverability, an asset impairment charge is recognized for the difference between the fair value and carrying value of the asset.

In addition to consideration of impairment upon the events or changes in circumstances described above, management regularly evaluates the remaining useful lives of its long-lived assets. If estimates are changed, the carrying value of affected assets is allocated over the remaining useful lives. In estimating the future cash flows for determining whether an asset is impaired, the Corporation groups its assets at the lowest level for which there are identifiable cash flows independent of other groups of assets. No impairment charge was recorded during the year ended December 31, 2021 or 2020.

(s) Goodwill and Intangible Assets

Goodwill and intangible assets are accounted for under ASC Topic 350, *Intangibles – Goodwill and Other*. Goodwill represents the excess of the aggregate purchase price over the fair value of net assets acquired in business combinations. Intangible assets represent the acquisition of the Rutgers Health brand name (see note 16). Identifiable intangible assets are initially recorded at fair value at the time of acquisition using the income approach. Goodwill and intangible assets have indefinite useful lives and are not amortized, but are subjected to impairment tests. The Corporation performs impairment testing at least annually or more frequently if events or circumstances change creating a reasonable possibility that an impairment may exist. Included in other assets are goodwill and intangible assets of approximately \$7,000 and \$45,000, respectively, at both December 31, 2021 and 2020.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

(3) COVID-19 Pandemic and Government Funding

On March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The pandemic adversely affected the Corporation's results of operations during 2020 and continued to affect the Corporation's results during 2021. However, the Corporation experienced a gradual and steady recovery in volumes in 2021 as compared to 2020 despite the surges caused by the Delta and Omicron variants.

On March 27, 2020, the President signed into law the CARES Act, which provides economic assistance to a wide array of industries, including healthcare. The CARES Act provides financial relief under several programs including a funding advance of Medicare payments, deferral of the employer portion of payroll taxes and establishment of the Provider Relief Fund (PRF). The U.S. Department of Health and Human Services (HHS) is expected to provide \$175,000,000 to assist healthcare providers in the recovery of lost revenues attributable to COVID-19 and healthcare-related expenses. Under the PRF, the Corporation has received approximately \$47,000 and \$636,000 for the years ended December 31, 2021 and 2020. These funds are considered a grant that is not subject to repayment, provided the Corporation maintains compliance with the related terms, conditions, and reporting requirements of the grant set forth by HHS. The compliance and reporting requirements, as issued and updated by HHS, may continue to evolve, which could impact the amounts recognized by the Corporation through this program. The Corporation has recognized approximately \$65,110 and \$570,657 as CARES Act grant revenue for the years ended December 31, 2021 and 2020. The remaining deferred payments may be recognized as operating revenue in future periods, subject to compliance with current rules and conditions and ongoing regulatory clarifications.

During the year ended December 31, 2020, the Corporation received approximately \$556,000 in Medicare payment advances under the Medicare Accelerated and Advanced Payment Program. Medicare started recouping these advances in April 2021 with final recoupments expected by August 2022. As of December 31, 2021, approximately \$207,000 has been recouped, with the balance of approximately \$349,000 recorded in the current portion of estimated amounts due to third party payors. As of December 31, 2020, approximately \$212,000 is recorded in current portion of estimated amounts due to third-party payors, with the balance of approximately \$344,000 recorded as long-term in the consolidated balance sheet.

The Corporation elected to defer the deposit and payment of the employer's share of Social Security taxes incurred from March 27, 2020 through December 31, 2021 as allowed under the CARES Act. The program requires payment of 50% of the deferred taxes by December 31, 2021 and 50% by December 31, 2022. As of December 31, 2020, the Corporation accumulated approximately \$88,000 of deferred employer payroll taxes that are recorded within accrued expenses and other current liabilities and other liabilities in the consolidated balance sheet. As of December 31, 2021, approximately \$46,000 of this amount was repaid, the balance of approximately \$42,000 is included in accrued expenses and other current liabilities.

During 2021, the Corporation applied for and received approval for the reimbursement of qualifying expenses under the Federal Emergency Management Agency (FEMA). For the year ended December 31, 2021, the Corporation recognized approximately \$94,000 of FEMA funds within other revenue in the consolidated statement of operations.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

(4) Charity Care and Community Benefit

In accordance with the Corporation's mission and philosophy, the Corporation's hospitals and affiliates commit substantial resources to both the indigent population and the broader community. The Corporation's charity care policy is to provide care without regard to the patient's ability to pay for services rendered. To the extent that patients do not have the ability to pay, services rendered to those patients are reported as charity care. The Corporation's hospitals and affiliates also provide other benefits through a broad range of community service programs and charitable activities. The amount of charity care, community service programs, and charitable activities, at estimated cost, provided to the indigent population and broader community for the years ended December 31, 2021 and 2020 is as follows:

	 2021	2020
Cost of charity care and community benefit programs: Estimated cost of charity care provided, less state subsidy		
	\$ 141,357	142,473
Unpaid cost of public programs, Medicaid, and other		
means – tested programs	434,505	413,925
Other programs:		
Cash and in-kind donations	\$ 2,934	3,528
Education and research	82,243	65,137
Subsidized departments	116,066	83,611
Other community benefits	12,224	21,213

The Corporation's hospitals utilize a cost to charge ratio methodology to convert charity care to cost. The cost to charge ratio is calculated utilizing the Corporation's cost accounting system or filed cost reports.

The State of New Jersey's regulations provide for the distribution of funds from a Charity Care Fund, which is intended to partially offset the cost of services provided to the uninsured. For the years ended December 31, 2021 and 2020, the Corporation's hospitals received distributions from the Charity Care Fund of \$19,934 and \$13,397, respectively, which are included in patient service revenue.

(5) Healthcare Reimbursement System

(a) The Corporation records patient service revenue at the amount that reflects the consideration to which the Corporation expects to be entitled in exchange for providing patient care. Patient service revenue consists of amounts charged for services rendered less estimated discounts for contractual and other allowances for patients covered by Medicare, Medicaid, and other health plans and discounts offered to patients under the Corporation's uninsured discount program.

The Medicare program currently pays for most services at predetermined rates; however, certain services and specified expenses continue to be reimbursed on a cost basis. The Medicaid program also currently reimburses the Corporation at predetermined rates for inpatient services and on a cost reimbursement methodology for outpatient services. Regulations require annual retroactive settlements

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

for cost-based reimbursement and other payment arrangements through cost reports filed by the Corporation.

The Corporation has also entered into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. These agreements have retrospective audit clauses, allowing the payor to review and adjust claims subsequent to initial payment.

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. As a result, there is a possibility that recorded estimates could change by a material amount. In accounting for Medicare and Medicaid cost report settlements, the Corporation records all third-party receivables and liabilities at their estimated realizable values. Management periodically reviews recorded amounts receivable from, or payable to, third-party payors and adjusts these balances as new information becomes available. In addition, revenue received under certain third-party agreements is subject to audit.

During the years ended December 31, 2021 and 2020, certain of the Corporation's prior year third-party cost reports were audited and settled, or tentatively settled by third-party payors. Adjustments resulting from such audits, settlements, and management reviews are reflected as adjustments to patient service revenue in the period that the adjustments become known. Accordingly, the Corporation evaluated the results of these settlements on its open cost reports. The effect of cost report settlements and other adjustments increased patient service revenue by approximately \$16,915 and \$15,755 for the years ended December 31, 2021 and 2020, respectively. Although certain other prior year cost reports submitted to third-party payors remain subject to audit and retroactive adjustment, management does not expect any material adverse settlements. Medicare cost reports for all years prior to 2017 have been audited and settled. Medicaid cost reports for all years prior to 2019 have been audited for all acute care hospitals. For the pediatric rehabilitation hospital, Medicaid cost reports have been audited by the fiscal intermediary through 2019. Settlement has been finalized through 2019. The fiscal intermediary may reopen certain years related to specific settlement items in the cost report year.

The Corporation has a compliance program to monitor conformity with applicable laws and regulations, but the possibility of future government review and interpretation exists. The Corporation is not aware of any significant pending or threatened investigations involving allegations of potential wrongdoing.

- (b) The Corporation and others in the healthcare industry are subject to certain inherent risks, including the following:
 - Substantial dependence on revenue derived from reimbursement by the Federal Medicare and State Medicaid programs that have been reduced in recent years and which entail exposure to various healthcare fraud statutes;
 - Government regulations, government budgetary constraints, and proposed legislative and regulatory changes.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

Such inherent risks require the use of certain management estimates in the preparation of the Corporation's consolidated financial statements, and it is reasonably possible that a change in such estimates may occur. Management of the Corporation believes that adequate provision has been made in the consolidated financial statements for the matters discussed above and their ultimate resolution will not have a material effect on the consolidated financial statements.

(6) Investments and Assets Limited or Restricted as to Use

Investments and assets limited or restricted as to use consist of the following:

		December 31	
	_	2021	2020
Investments and assets limited or restricted as to use:			
Cash and cash equivalents and money market funds	\$	933,698	697,663
Government obligations/municipal bonds		340,876	453,014
Corporate bonds		1,196,208	1,179,987
Certificates of deposit		5,914	5,853
Mutual funds		1,859,288	1,882,570
Equity securities		540,805	408,568
Unit investment trusts		1,269	1,061
Asset-backed securities		377,889	417,747
Mortgage-backed securities		153,818	135,484
Alternative investments		983,930	800,096
Pledges receivable, net		119,167	31,400
Other investments		2,634	2,699
Accrued interest	_	11,923	10,943
Total investments and assets limited or restricted			
as to use	\$ _	6,527,419	6,027,085

These amounts are reflected in the consolidated balance sheets as follows:

		December 31		
	_	2021	2020	
Current portion:				
Investments	\$	755,551	578,074	
Assets limited or restricted as to use		90,605	142,603	
Noncurrent assets limited or restricted as to use		819,128	273,902	
Investments	_	4,862,135	5,032,506	
	\$	6,527,419	6,027,085	

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

Investments and assets limited or restricted as to use are classified as follows:

		December 31		
		2021	2020	
Investments	\$	5,617,686	5,610,580	
Self-insurance funds		24,802	25,108	
Donor-restricted funds and pledges receivable, net		234,884	151,467	
Funds held by bond trustees under bond indenture agreements		536,456	53,677	
Internally designated funds for specific use		2,870	60,840	
Other limited use funds	_	110,721	125,413	
	\$_	6,527,419	6,027,085	

Assets held under bond indenture agreements are maintained for the following purposes:

		December 31		
	_	2021	2020	
Capital project funds	\$	477,559		
Interest funds		58,889	53,669	
Principal funds		8	8	
	\$	536,456	53,677	

The Corporation's investments are exposed to various kinds and levels of risk. Fixed income securities, including fixed income mutual funds, expose the Corporation to interest rate risk, credit risk, and liquidity risk. As interest rates change, the values of many fixed income securities are affected. Credit risk is the risk that the obligor of the security will not fulfill its obligation. Liquidity risk is a risk that a financial asset may not be readily sold.

Corporate bonds, equity mutual funds, equity securities, and commercial mortgage-backed securities expose the Corporation to market risk, performance risk, and liquidity risk. Market risk is the risk associated with major movements of the equity markets, both foreign and domestic. Performance risk is the risk associated with a particular fund's operating performance. Liquidity risk, as previously defined, tends to be higher for international funds and small capitalization equity funds.

The Corporation has incorporated an Investment Policy Statement (IPS) into its investment program. The IPS, which has been formally adopted by the Board of Trustees, contains standards designed to ensure adequate diversification by asset category and geography. The IPS also limits fixed income investments by credit rating, which serves to further mitigate the risk associated with the investment program. At December 31, 2021 and 2020, management believes that its investment positions are in accordance with guidelines established by the IPS.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

(7) Liquidity and Availability of Resources

Financial assets available within one year of the balance sheet date for general expenditures such as operating expenses and construction costs not financed with debt are as follows:

		December 31		
	_	2021	2020	
Cash and cash equivalents	\$	154,095	100,380	
Short-term investments		755,551	578,074	
Patient accounts receivable		678,737	589,224	
Estimated amounts due from third party payors and other				
current assets	_	295,329	88,428	
	\$	1,883,712	1,356,106	

Current financial assets not available for general use because of contractual or donor-imposed restrictions were \$90,605 and \$142,603 at December 31, 2021 and 2020, respectively. Amounts not available for general use include amounts set aside for scheduled principal payments on debt, self-insurance funds, and perpetual, time, and purpose-restricted assets.

As of December 31, 2021, the Corporation has unrestricted cash and investments on hand to cover 335 days of operating expenses. Day's cash on hand includes Medicare advances of approximately \$349,000 received as part of the CARES Act. The Corporation's practice is to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. In addition, the Corporation invests cash in excess of daily requirements in short-term investments. Besides short-term investments, the Corporation has \$4,862,135 classified as long-term investments at December 31, 2021, of which most is available for general use. In the event of an unanticipated liquidity need, the Corporation could draw upon a \$50,000 secured revolving promissory note (note 10).

(8) Fair Value Measurements

ASC Topic 820, *Fair Value Measurement*, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include cash and cash equivalents and debt and equity securities that are traded in an active exchange market.

Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted market prices that are traded less frequently than exchange-traded instruments. This category generally includes certain U.S. government and agency mortgage-backed debt securities and corporate bonds.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. The Corporation currently holds no Level 3 investments.

The following tables present the Corporation's fair value hierarchy for those assets measured at fair value on a recurring basis, and exclude pledges receivable, net, other investments, and accrued interest receivable as of December 31, 2021 and 2020:

		December 31, 2021						
	Fair value	Level 1	Level 2	Level 3	NAV			
Investment categories:								
Cash and cash equivalents								
and money market funds	\$ 933,698	933,698	_	_	_			
Equity securities	540,805	540,805	_	_				
Equity mutual funds	1,457,273	1,422,936	34,337					
Fixed income mutual funds	402,015	402,015	· —	_				
Certificates of deposit	5,914	· —	5,914	_	_			
Unit investment trusts	1,269	1,269	· —	_	_			
Commercial mortgage-backed								
securities	153,818	_	153,818	_	_			
Corporate bonds	1,196,208	_	1,196,208	_	_			
Asset-backed securities	377,889	_	377,889	_	_			
Government bonds	176,092	_	176,092					
Government mortgage-backed								
securities	121,631	_	121,631	_				
Municipal bonds	43,153	_	43,153	_				
Alternative investments	983,930	. <u>—</u>			983,930			
Total	\$ 6,393,695	3,300,723	2,109,042		983,930			

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

	December 31, 2020							
		Fair value	Level 1	Level 2	Level 3	NAV		
Investment categories:								
Cash and cash equivalents								
and money market funds	\$	697,663	697,663	_	_	_		
Equity securities		408,568	408,568	_	_	_		
Equity mutual funds		1,510,039	1,510,039	_	_	_		
Fixed income mutual funds		372,531	372,531	_	_	_		
Certificates of deposit		5,853	_	5,853	_	_		
Unit investment trusts		1,061	1,061	_	_	_		
Commercial mortgage-backed								
securities		135,484	_	135,484	_	_		
Corporate bonds		1,179,987	_	1,179,987	_	_		
Asset-backed securities		417,747	_	417,747	_	_		
Government bonds		175,878	_	175,878	_	_		
Government mortgage-backed								
securities		214,319	_	214,319	_	_		
Municipal bonds		62,817	_	62,817	_	_		
Alternative investments	_	800,096				800,096		
Total	\$	5,982,043	2,989,862	2,192,085		800,096		

The following discussion describes the valuation methodologies used for financial assets measured at fair value for investment and pension plan assets. The techniques utilized in estimating the fair values are affected by the assumptions used, including discount rates and estimates of the amount and timing of future cash flows.

Fair value estimates are made at a specific point in time, based on available market information and judgments about the financial asset, including estimates of timing, amount of expected future cash flows, and the credit standing of the issuer. In some cases, the fair value estimates cannot be substantiated by comparison to independent markets. The disclosed fair value may not be realized in the immediate settlement of the financial asset. In addition, the disclosed fair values do not reflect any premium or discount that could result from offering for sale at one time an entire holding of a particular financial asset. Potential taxes and other expenses that would be incurred in an actual sale or settlement are not reflected in amounts disclosed. Care should be exercised in deriving conclusions about the Corporation's business, its value, or consolidated financial position based on the fair value information of financial assets presented.

Fair values for the Corporation's fixed income securities are based on prices provided by its investment managers and its custodian bank. Both the investment managers and the custodian bank use a variety of pricing sources to determine market valuations. Inputs include direct or indirectly observable inputs (other than Level 1 inputs) such as quoted prices for similar assets or liabilities exchanged in active or inactive markets and quoted prices for identical assets or liabilities in inactive markets; other inputs that may be considered in fair value determination include interest rates and yield curves, volatilities, and credit risk. Pricing evaluations generally reflect discounted expected future cash flows, which incorporate yield curves for instruments with similar characteristics, such as credit rating, duration, and yields. Each designates

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

specific pricing services or indexes for each sector of the market based upon the provider's expertise. The Corporation's fixed income securities portfolio is highly liquid, which allows for a high percentage of the portfolio to be priced through pricing services.

Fair values of equity securities have been determined by the Corporation from observable market quotations, when available.

Mutual funds and unit investment trusts are valued at the NAV of shares held at year-end, based on published market quotations on active markets.

Fair values of commercial mortgage-backed securities and asset-backed securities have been determined by the Corporation based on a discounted future cash flows methodology, using current market interest rate data adjusted for inherent credit risk, or quoted market prices and recent transactions, when available.

Fair values of U.S. government bonds/municipal bonds and corporate bonds have been determined by the Corporation from observable market quotations, when available. Because of the nature of these assets, carrying amounts approximate fair values, which have been determined from public quotations, when available.

Fair values of bank loans are determined by the Corporation using quoted prices of securities with similar coupon rates and maturity dates or discounted cash flows.

The following tables summarize redemption terms and the Corporation's commitments for the hedge funds and others as of December 31, 2021 and 2020:

	_	2021			
Description of investment		Carrying value	Unfunded commitment	Redemption frequency	Redemption notice required
Hedge funds	\$	381,797	_	Monthly – annually	45–90 days written notice
Private equity		155,656	106,861	_	_
Real estate		231,939	44,508	Quarterly	90 days written notice
Other	_	214,538	17,830	_	_
	\$ _	983,930	169,199		

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

		2020				
Description of investment		Carrying value	Unfunded commitment	Redemption frequency	Redemption notice required	
Hedge funds	\$	314,635	_	Monthly – annually	45–90 days written notice	
Private equity		113,893	129,948	_	_	
Real estate		192,826	21,094	Quarterly	90 days written notice	
Other	_	178,742	21,636	_	_	
	\$_	800,096	172,678			

Investments in hedge funds, interests in investment funds with complex portfolio-construction and risk management techniques, are typically carried at estimated fair value based on the NAV of the shares in each investment company or partnership. Changes in unrealized gains or losses on investments, including those for which partial liquidations were effected in the course of the year, are calculated as the difference between the NAV of the investment at year-end less the NAV of the investment at the beginning of the year, as adjusted for contributions and redemptions made during the year. At December 31, 2021, the Corporation holds \$154,028 of investments in hedge funds, which are subject to a 50% withdrawal limitation on the invested balance per quarter. As of December 31, 2021, \$50,000 of the balance was subject to lock-up which expired on February 1, 2022. Generally, no dividends or other distributions are paid.

Investments in private equity funds, typically structured as limited partnership interests, are carried at fair value estimated using NAV or equivalent as determined by the general partner in the absence of readily ascertainable market values. Distributions under this investment structure are made to investors through the liquidation of the underlying assets. Voluntary redemptions are generally not permitted by limited partners and investments in these partnership interests are through the life of the fund. The fair value of limited partnership interests is generally based on fair value capital balances reported by the underlying partnerships, subject to management review and adjustment.

Real estate funds invest primarily in institutional quality commercial and residential real estate assets within the U.S. and investments in publicly traded real estate investment trusts. Fair value is estimated based on the NAV of the shares in each partnership. The Partnership distributes current income to the partners on a quarterly basis based on each partners' interest. Partners can choose to participate in a reinvestment plan in which all distributions are automatically invested in additional units. Redemptions can generally be made quarterly with 90 days' prior written notice after an initial lock-up period expires.

Investments in other alternative investments consist of private debt funds structured as a limited partnership interest with ability to invest in short-term opportunities, and are carried at fair value estimated using NAV or equivalent as determined by the general partner in the absence of readily ascertainable market values. Distributions under this investment structure are made to investors through the liquidation of the underlying assets. Voluntary redemptions are not permitted and investment is through the life of the fund. The Corporation also invests in certain venture capital funds. Investments in venture capital funds,

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

typically structured as limited partnerships, consist of ownership stakes in small to medium sized start-up firms. These firms generally have high growth potential and are characterized by higher risk/reward profiles. Distributions under this investment structure are typically made to investors through the liquidation of the underlying assets. Voluntary redemptions are generally not permitted by limited partners and investments in these partnership interests are through the life of the fund.

(9) Property, Plant, and Equipment

Property, plant, and equipment consist of the following as of December 31, 2021 and 2020:

	_	2021	2020
Land and improvements	\$	167,565	155,987
Buildings and leasehold improvements		3,319,333	3,180,964
Fixed equipment		435,393	417,208
Major movable equipment		2,181,221	2,039,051
Real estate and equipment under finance leases		55,502	52,919
		6,159,014	5,846,129
Less accumulated depreciation and amortization (including accumulated amortization of real estate and equipment under			
finance leases of \$23,626 and \$19,822)		3,858,717	3,632,227
		2,300,297	2,213,902
Construction in progress	_	609,869	349,507
Property, plant, and equipment, net	\$	2,910,166	2,563,409

The Corporation will fund the construction of a new clinical and research building for the Rutgers Cancer Institute of New Jersey (CINJ). The new building is adjacent to, and integrated with, RWJUH New Brunswick. In June 2021, the Corporation broke ground on the free standing cancer hospital. The estimated cost is expected to be approximately \$735,000. For the year ended December 31, 2021, approximately \$135,000 has been incurred related to this project.

As of December 31, 2021, the Corporation had committed approximately \$950,000 to complete the construction of the Rutgers CINJ project noted above and other renovation and expansion projects at various affiliates of the Corporation as well as amounts committed for the EPIC project (note 13e).

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

(10) Long-Term Debt

Long-term debt consists of the following:

	December 31	
	2021	2020
Master Trust indebtedness:		
New Jersey Health Care Facilities Financing Authority		
(NJHCFFA) Revenue and Refunding Bonds:		
RWJ Barnabas Health Obligated Group Issue, 2021A		
\$351,355 serial bonds maturing through July 1,		
2045 with interest rates ranging from 4.00% to		
5.00%; \$400,490 of term bonds maturing July 1, 2051		
with interest rates ranging from 2.040% to 2.625% \$	751,845	_
RWJ Barnabas Health Obligated Group Issue,		
Series 2019A Serial Bonds maturing through July 1,		
2029 with an interest rate of 5.00%	15,470	17,490
RWJ Barnabas Health Obligated Group Issue, Series		
2019B-1 Five Year Put Bonds maturing on July 1,		
2043 with an interest rate of 5.00%	69,725	69,725
RWJ Barnabas Health Obligated Group Issue, Series		
2019B-2 Six Year Put Bonds maturing on July 1,		
2042 with an interest rate of 5.00%	70,555	70,555
RWJ Barnabas Health Obligated Group Issue, Series		
2019B-3 Seven Year Put Bonds maturing on July 1,		
2045 with an interest rate of 5.00%	70,550	70,550
RWJ Barnabas Health Obligated Group Issue, Series		
2017A (previously Children's Specialized Hospital		
Issue, Series 2013A) maturing on July 1, 2036 with		
an interest rate of 3.03%	7,438	7,829
RWJ Barnabas Health Obligated Group Issue,		
Series 2016A \$399,565 serial bonds maturing through		
July 1, 2036 with interest rates ranging from 3.50% to		
5.00%; \$279,570 of term bonds maturing on July 1,		
2043 with interest rates ranging from 4.00% to 5.00%	679,135	679,135
Barnabas Health Issue, Series 2014A term bonds		
\$100,000 maturing on July 1, 2044 with an interest		
rate of 5.00%; \$29,925 maturing on July 1, 2044 with	400.005	100.05-
an interest rate of 4.25%	129,925	129,925

Notes to Consolidated Financial Statements December 31, 2021 and 2020 (In thousands)

		Decem	ber 31
		2021	2020
Robert Wood Johnson University Hospital Issue, Series 2014A \$11,075 serial bonds maturing through 2034 with an interest rate of 5.00%; \$45,210 term bonds maturing from 2039 to 2043 with an interest rate of 5.00%	\$	55,925	55,925
Robert Wood Johnson University Hospital Issue, Series 2013A \$9,230 serial bonds maturing through 2023 with interest rates ranging from 3.00% to 5.00%; \$93,285 term bonds maturing from 2024 to 2043 with	*		,
interest rates ranging from 5.25% to 5.50% Barnabas Health Issue, Series 2012A serial bonds		98,125	100,375
maturing through 2022 with an interest rate of 5.00% RWJ Barnabas Health, Series 2019 serial bonds maturity through July 1, 2049 with an interest rate of		9,000	90,250
3.48%		302,333	302,333
RWJ Barnabas Health Private Placement Taxable Notes, Series 2018 maturing through July 1, 2044 with interest rates ranging from 4.04% to 4.40% RWJ Barnabas Health Taxable Revenue Bonds, Series		300,000	300,000
2016 \$100,000 maturing July 1, 2026 with an interest rate of 2.954%; \$394,952 maturing July 1, 2046 with an interest rate of 3.949% Barnabas Health System Taxable Revenue Bonds, Series 2012 term bonds maturing on July 1, 2028		494,952	494,952
with an interest rate of 4.00%		81,240	81,240
Total Master Trust Indebtedness		3,136,218	2,470,284
Finance leases with various interest rates		32,166	33,982
Total long-term debt		3,168,384	2,504,266
Plus unamortized bond premium Less:		218,751	114,557
Unamortized bond discount		1,160	1,376
Deferred financing costs, net		19,572	15,820
Current portion		38,468	9,224
Long-term portion	\$	3,327,935	2,592,403

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

Under the terms of the Master Trust Indenture (MTI), Barnabas Health, Inc., Children's Specialized Hospital (CSH), Clara Maass Medical Center, Community Medical Center, Jersey City Medical Center, Monmouth Medical Center (including Monmouth Medical Center, Southern Campus), Newark Beth Israel Medical Center, RWJ Barnabas Health, Inc., Robert Wood Johnson University Hospital (RWJUH), Robert Wood Johnson University Hospital at Hamilton, Robert Wood Johnson University Hospital Rahway, and Cooperman Barnabas Medical Center (CBMC), formerly known as Saint Barnabas Medical Center, are members of an Obligated Group. Substantially all of the Corporation's debt is subject to the provisions of the MTI.

To secure its payment obligations, the Obligated Group has granted to the Trustee a first lien and security interest in the gross revenue of each member of the Obligated Group.

Obligated Group members are jointly and severally liable under the MTI. The Corporation does have the right to name designated affiliates. Though designated affiliates are not obligated to make debt service payments on the obligations under the MTI, the Corporation may cause each designated affiliate to transfer such amounts as necessary to enable the Obligated Group members to comply with the terms of the MTI, including payment of the outstanding obligations.

The Corporation's Obligated Group is required to maintain certain financial covenants in connection with the NJHCFFA and credit arrangements with a consortium of banks, including JPMorgan Chase Bank, N.A. (JPMorgan), TD Bank and U.S. Bank.

On August 19, 2021, the Corporation legally defeased all of the outstanding New Jersey Health Care Facilities Financing Authority Revenue and Refunding Bonds, Barnabas Health Issue, Series 2012A that mature on and after July 1, 2023. The principal amount of the defeased bonds was \$81,250. U.S. Bank National Association is the bond trustee and escrow agent. The defeased bonds will be called for optional redemption on July 1, 2022 at a redemption price equal to 100% of the principal amount plus accrued interest. The principal amount of the remaining Series 2012A Bonds that was not defeased is \$9,000 and will be called for redemption on July 1, 2022 with accrued interest due on January 1, 2022 and July 1, 2022. The transaction resulted in a gain on extinguishment of debt of \$702 which is recorded in other, net within nonoperating revenue.

On September 30, 2021, the Obligated Group issued New Jersey Health Care Facilities Financing Authority, RWJ Barnabas Health Revenue Bonds, Series 2021A in the amount of \$751,845 as obligations under the MTI. These bonds mature on July 1, 2051 and consist of principal of \$351,355 and \$400,490 in Serial and Term Bonds, respectively. Series 2021A was issued at a premium of \$118,456 for a total source of funds of \$870,301. Principal payments are due annually on July 1 and interest payments are due semi-annually until maturity. The bond proceeds will be used to fund the construction of the Rutgers CINJ as well as various other capital projects. As of December 31, 2021, \$343,893 of the bond proceeds was reimbursed from the construction fund.

On March 25, 2020, April 7, 2020, and June 30, 2021 the Corporation entered into forward interest rate swap agreements with JPMorgan, Bank of America, and U.S. Bank, respectively. Under the terms of these agreements, the Corporation is paying fixed interest rates ranging from 0.90275% to 1.3625% in exchange for variable rate payments equal to 70% of the effective Federal funds rate. The notional amounts on these swap agreements are tied to the outstanding principal on the underlying bond series. The Corporation has

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

the option to terminate the interest rate swap agreements on or before July 1, 2034. As of December 31, 2021 and 2020, the fair value of the interest rate swap agreements, net of a credit value adjustment of \$1,103 and \$739, was \$6,145 and \$4,509, respectively, and is included in other assets, net.

On March 31, 2021, the Corporation entered into a secured revolving promissory note (the Note) for the principal amount of \$50,000 with JPM for routine working capital needs. The Note contained an accordion feature that allowed the Corporation to increase the loan by an additional \$50,000. The terms of the Note include a commitment fee of 0.12% and a LIBOR spread at 0.55%. As of December 31, 2021, \$5,575 of the Note was used in the form of standby letters of credit (LOC) that provides liquidity support for the Corporation's self-insured workers' compensation and other programs. There was no cash drawn from the Note during the term. The Note expired on March 31, 2022 and was replaced with a \$50,000 secured revolving promissory note (New Note) with JPM expiring on March 31, 2023. The terms of the New Note include a commitment fee of 0.12%. The interest rate is based on an adjusted term SOFR Rate for the interest period plus 0.55% per annum. As of April 27, 2022, there were no borrowings outstanding.

Scheduled maturities on long-term debt and future minimum payments on finance lease obligations at December 31, 2021 are as follows:

		Long-term	Finance	
	_	debt	leases	Total
2022	\$	34,240	5,239	39,479
2023		37,734	4,398	42,132
2024		45,686	3,741	49,427
2025		46,046	3,743	49,789
2026		132,596	3,755	136,351
Thereafter	_	2,839,916	19,280	2,859,196
Total		3,136,218	40,156	3,176,374
Plus unamortized bond premium		218,751	_	218,751
Less:				
Amount representing interest on finance				
lease obligations		_	7,990	7,990
Unamortized bond discount		1,160	_	1,160
Deferred financing costs, net		19,572	_	19,572
Current portion	_	34,240	4,228	38,468
Long-term portion	\$_	3,299,997	27,938	3,327,935

(11) Employee Benefit Plans

The Corporation maintains a single noncontributory defined-benefit plan, the RWJ Barnabas Health Retirement Income Plan (the RWJBH Plan). Participation in the RWJBH Plan is closed to new entrants and is currently frozen to future benefit accruals. Benefits under the RWJBH Plan are substantially based on

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

years of service and employee's career earnings. The Corporation will contribute to the RWJBH Plan based on actuarially determined amounts necessary to provide assets sufficient to meet anticipated benefit payments to plan participants and to meet the minimum funding requirements of the Employee Retirement Income Security Act of 1974, as amended by the Pension Protection Act of 2006, and Internal Revenue Service regulations.

GAAP requires recognition on the balance sheet of the funded status of defined-benefit pension plans and the recognition in net assets without donor restrictions of unrecognized actuarial gains and losses and prior service costs and credits. The funded status is measured as the difference between the fair value of the RWJBH Plan's assets and the projected benefit obligation of the RWJBH Plan.

Included in net assets without donor restriction at December 31, 2021 and 2020 are the following amounts that have not yet been recognized in net periodic pension cost: unrecognized prior service cost of approximately \$2,431 and \$2,551, respectively, and unrecognized actuarial losses of approximately \$254,651 and \$255,002, respectively. Unrecognized prior service cost is the impact of changes in plan benefits applied retrospectively to employee service previously rendered. Unrecognized actuarial losses represent unexpected changes in the projected benefit obligation and plan assets over time, primarily due to changes in assumed discount rates and investment experience. Using the measurement date of December 31, the following table sets forth the funded status of the RWJBH Plan and the amounts recognized in the Corporation's consolidated financial statements:

	December 31			
	-	2021	2020	
Changes in benefit obligation:				
Benefit obligation at beginning of period	\$	1,128,203	1,050,229	
Interest cost		30,703	36,641	
Actuarial (gains) losses		(19,011)	110,975	
Benefits paid and expenses	_	(67,603)	(69,642)	
Benefit obligation at end of year	-	1,072,292	1,128,203	
Change in plan assets:				
Fair value of plan assets at beginning of period		1,096,738	1,028,675	
Actual return on plan assets		9,739	133,505	
Employer contributions		4,400	4,200	
Benefits paid and expenses	_	(67,603)	(69,642)	
Fair value of plan assets at end of year	-	1,043,274	1,096,738	
Funded status – accrued pension liability	\$	(29,018)	(31,465)	

The actuarial gain in 2021 resulted in an overall decrease in the December 31, 2021 projected benefit obligation of approximately \$19,011, which was primarily attributable to an increase in the discount rate assumption from 2020 to 2021.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

The actuarial loss in 2020 resulted in an overall increase in December 31, 2020 projected benefit obligation of approximately \$110,975, which was primarily attributable to a decrease in the discount rate assumption from 2019 to 2020.

During 2021 and 2020, the Society of Actuaries published updated mortality table MP-2021 and MP-2020. The Corporation utilized the updated mortality tables resulting in an increase in the projected benefit obligations in the amount of \$3,900 at December 31, 2021 and a decrease in the projected benefit obligation in the amount of \$5,100 at December 31, 2020.

The actuarially computed net periodic pension cost for the years ended December 31, 2021 and 2020 included the following components, which are included in other nonoperating revenue, net:

	 2021	2020	
Interest costs	\$ 30,703	36,641	
Expected return on plan assets	(34,799)	(40,162)	
Amortization of actuarial loss and prior service credit	 6,520	6,349	
Net periodic pension cost	\$ 2,424	2,828	

The projected unit credit method is the actuarial cost method used to compute pension expense.

The weighted average assumptions used in determining the net periodic pension cost was discount rates of 2.82% and 3.59%, an expected long-term rate of return on plan assets of 3.30% and 4.05% and the weighted average interest crediting rate for cash balance plans was 2.25% and 2.30% for the years ended December 31, 2021 and 2020, respectively.

The weighted average assumption used in the accounting for the projected benefit obligation was a discount rate of 3.09% and 2.82% and the weighted average interest crediting rate for cash balance plans was 2.25% as of December 31, 2021 and 2020, respectively.

Expected benefit payments by year as of December 31, 2021 are as follows:

2022	\$ 72,912
2023	74,154
2024	74,824
2025	77,470
2026	78,845
2027–2031	328,699

The consolidated assets of the RWJBH Plan are managed under a liability-driven investment (LDI) strategy. Under the LDI strategy, the expected rate of return on plan assets at December 31, 2021 is based upon the assumption that plan assets will be invested primarily in fixed income and other related securities based upon their ability to perform similarly to the characteristics of the plan liabilities over time.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

The following tables present the Corporation's fair value hierarchy for those pension plan assets measured at fair value as of December 31, 2021 and 2020. At December 31, 2021 or 2020, the Corporation held no Level 3 assets.

			De	ecember 31, 202	21	
		Fair value	Level 1	Level 2	Level 3	NAV
Cash and cash equivalents	\$	90,654	90,654	_	_	_
Corporate bonds	•	471,512	<i>'</i> —	471,512	_	_
Government bonds		143,439	_	143,439	_	_
Bond funds		143,710	_	143,710	_	_
Bank loans		6,891	_	6,891	_	_
Other investments		13,728	_	13,728	_	_
Alternative investments	_	173,340				173,340
	\$_	1,043,274	90,654	779,280		173,340

		December 31, 2020				
		Fair value	Level 1	Level 2	Level 3	NAV
Cash and cash equivalents	\$	39,885	39,885	_	_	_
Corporate bonds		501,653	_	501,653	_	_
Government bonds		175,518	_	175,518	_	_
Bond funds		186,259	_	186,259	_	_
Bank loans		7,178	_	7,178	_	_
Other investments		14,208	_	14,208	_	_
Alternative investments	_	172,037				172,037
	\$_	1,096,738	39,885	884,816		172,037

The asset's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

Alternative investments include private equity investments, hedge funds, and other.

	2021						
Description of investment		Carrying value	Unfunded commitment	Redemption frequency	Redemption notice required		
Hedge fund	\$	33,607	_	Semi-annually	90 days		
Private equity		75,875	101,905	_	_		
Other	_	63,858		_	_		
	\$_	173,340	101,905				

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

		2020						
Description of investment		Carrying value	Unfunded commitment	Redemption frequency	Redemption notice required			
Hedge fund	\$	51,351	_	Semi-annually	90 days			
Private equity		70,343	82,833	_	_			
Other	_	50,343		_	_			
	\$_	172,037	82,833					

The Corporation maintains multiple defined-contribution retirement plans for its employees. Benefit expense for these plans for the years ended December 31, 2021 and 2020 was \$84,392 and \$83,041, respectively. The Corporation also has several supplemental executive retirement plans for certain key individuals. The plans were funded during 2021 and 2020 based upon the benefit formula as outlined in the plan documents.

(12) Leases

The following table presents the components of the ROU assets, liabilities, and expenses related to leases and their classification in the consolidated balance sheets and statements of operations as of and for the years ended December 31, 2021 and 2020:

	Classification in consolidated			
Components of lease balances	balance sheets	_	2021	2020
Assets:				
Operating lease assets	ROU asset	\$	258,089	269,663
Finance lease assets	Property, plant, and equipment, net	_	31,876	33,097
Total leased assets		\$_	289,965	302,760
Liabilities:				
Operating lease liabilities:				
Current	Lease obligations	\$	37,942	42,237
Long term	Lease obligations, net of current			
	portion		234,433	237,046
Total operating lease liabilities		_	272,375	279,283
Finance lease liabilities:				
Current	Long-term debt		4,228	4,562
Long term	Long-term debt, net of current			
	portion	_	27,938	29,420
Total finance lease liabilities			32,166	33,982
Total lease liabilities		\$	304,541	313,265

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

Classification in consolidated

Components of lease expense	statements of operations		2021	2020
Operating lease expense	Other operating expenses	\$	56,249	59,531
Finance lease expense: Amortization of leased assets	Depreciation and amortization		3.804	1,165
Interest on lease liabilities	Interest		1,138	1,542
Total finance lease expense			4,942	2,707
Variable and short-term lease expense	Other operating expenses	_	15,347	14,933
Total lease expense		\$	76,538	77,171

The Corporation determines if an arrangement is a lease at the inception of the contract. The ROU assets represent the Corporation's right to use the underlying assets for the lease term and the lease liabilities represent the Corporation's obligation to make lease payments arising from the leases. ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. An estimated incremental borrowing rate, which is derived from information available at the lease commencement date, is used to determine the present value of lease payments. The incremental borrowing rates for the portfolio of leases are based upon indicative borrowing rates for taxable debt with terms that correspond to the various lease terms.

The Corporation's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices, as well as medical and office equipment. Finance leases are primarily for real estate and medical equipment. Real estate lease agreements typically have initial terms of 5 to 10 years, and equipment lease agreements typically have initial terms between 2 and 5 years. The Corporation has certain long-term land leases whose original terms range from 50 to 98 years. Leases with an initial term of 12 months or less (short-term leases) are not recorded in the consolidated balance sheets.

Real estate leases may include one or more options to renew, with renewals that can extend the lease term from 1 to 20 years. The Corporation has the option to renew its land leases that can extend the lease term significantly. The exercise of lease renewal options is at the Corporation's sole discretion. Renewal options are assessed at the commencement date, modification date, and when a reassessment event has occurred. The renewal option is included in the lease term when it is reasonably certain to be exercised. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.

Certain lease agreements for real estate include payments based on actual common area maintenance expenses. These variable lease payments are recognized in other operating expenses, net, but are not included in the ROU asset or liability balances. Real estate leases generally include rental escalation clauses that are factored into the determination of lease expense when appropriate. Escalations based on an index, such as the Consumer Price Index, are estimated at the commencement date and differences to

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

the initial estimate are treated as variable lease payments. The lease agreements do not contain any material residual value guarantees, restrictions, or covenants.

The Corporation has elected the practical expedient that allows lessees to choose to not separate lease and nonlease components by class of underlying asset and is applying this expedient to all real estate asset classes. The Corporation elected the practical expedient package to not reassess at adoption (i) whether expired or existing contracts contain leases under the new definition of a lease, (ii) lease classification for expired or existing leases, or (iii) whether previously capitalized initial direct costs would qualify for capitalization under Topic 842.

Sublease income is included in other revenue in the consolidated statements of operations and amounted to \$4,981 and \$5,719 for the years ended December 31, 2021 and 2020, respectively.

The weighted average lease terms and discount rates for operating and finance leases at December 31, 2021 and 2020 are presented in the following table:

	2021	2020
Weighted average remaining lease term:		
Operating leases	10.2 years	9.7 years
Finance leases	10.5 years	11.2 years
Weighted average discount rate:		
Operating leases	3.40 %	3.55 %
Finance leases	3.96	3.97

Cash flow and other information related to leases is included in the following table for the years ended December 31, 2021 and 2020:

	2021	2020
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash outflows from operating leases	\$ 53,097	56,502
Operating cash inflows from operating leases	1,647	1,907
Operating cash outflows from finance leases	1,138	1,542
Financing cash outflows from finance leases	4,555	5,552
ROU assets obtained in exchange for lease obligations:		
Operating leases	\$ 19,459	89,147
Finance leases	2,739	1,169

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

Future maturities of lease liabilities at December 31, 2021 are presented in the following table:

	_	Operating leases	Finance leases	Total
2022	\$	42,214	5,239	47,453
2023		32,788	4,398	37,186
2024		28,190	3,741	31,931
2025		26,118	3,743	29,861
2026		23,654	3,755	27,409
Thereafter	_	153,899	19,280	173,179
Total lease payments		306,863	40,156	347,019
Less imputed interest	_	34,488	7,990	42,478
Total lease obligations		272,375	32,166	304,541
Less current obligations	_	37,942	4,228	42,170
Long-term lease obligations	\$_	234,433	27,938	262,371

(13) Commitments and Contingencies

(a) Professional and General Liabilities

Commercial Professional Insurance Co. Ltd. (CPIC), is an off-shore captive insurance company located in Bermuda, which writes professional liability, comprehensive general liability, and other casualty lines of business for the Corporation and its affiliates. CPIC is a wholly owned affiliate of CBMC and is consolidated in the accompanying consolidated financial statements. Investments and other assets maintained by CPIC are reported in assets limited as to use under externally designated or restricted assets in the consolidated balance sheets. The Corporation has estimated a range of losses for its potential liability for professional liability, comprehensive general liability, and other casualty lines of business related to CPIC based upon its own past experience and industry experience data. These estimates include ultimate costs for unreported incidents and losses not covered by current insurance limits on a present value basis.

For policy years beginning July 1, 2004, CPIC provides payment of claims on a reimbursement basis for the Corporation's self-insurance program. For professional liability, the most recent limits are \$1 million for each medical incident with a \$3 million aggregate for CSH claims, \$10 million for each medical incident with no aggregate for all other facilities, and a buffer layer of \$5 million for each medical incident with an annual aggregate limit of \$5 million. For general liability, the limit is \$1 million for each and every general liability occurrence with no aggregate. Prior to July 1, 2018, the Corporation purchased excess coverage of \$150 million from various carriers for amounts in excess of CPIC's retained limits. Beginning July 1, 2018, the excess coverage is funded through CPIC. CPIC purchases reinsurance through various carriers.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

Prior to December 31, 2016, certain affiliates of the Corporation were insured through Systems and Affiliated Members Limited (SAAML). In February 2017, CPIC and SAAML finalized a merger, with CPIC as the surviving company, at which time all affiliates were insured by CPIC. CPIC issues policies providing professional liability and comprehensive general liability coverage for all the Corporation's affiliates and subsidiaries under a combined insurance program.

At December 31, 2021 and 2020, total liabilities, which include tail coverage, were \$334,286 and \$269,601, respectively. The liabilities have been discounted at 2.5% and are included in self-insurance liabilities in the accompanying consolidated balance sheets. The undiscounted liability was \$354,586 and \$287,986 as of December 31, 2021 and 2020, respectively. The liabilities also include \$38,765 and \$21,197 of claims at December 31, 2021 and 2020, respectively, which are expected to be reimbursed by CPIC. Such amounts are included in other assets, net, in the accompanying consolidated balance sheets.

(b) Workers' Compensation

The Corporation is self-insured for the majority of workers' compensation benefits and has a commercial insurance policy excess of \$1,000 each and every claim. At December 31, 2021 and 2020, the accrual for estimated workers' compensation claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported and totaled \$59,812 and \$55,405, respectively. The liabilities also include \$10,616 and \$11,072 of claims as of December 31, 2021 and 2020, respectively, which are expected to be reimbursed by the excess carrier. Such amounts are included in other assets, net. The Corporation's obligation to pay workers' compensation benefits from the runoff of a legacy workers' compensation program, which ended in 2013, is supported by an unsecured letter of credit in the amount of \$5,400 (note 10).

(c) Employee Health Insurance

The Corporation maintains self-insured employee health benefit programs to provide coverage for its employees. At December 31, 2021 and 2020, the accrual for estimated employee health insurance claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported of approximately \$31,083 and \$23,865, respectively, and is included in self-insurance liabilities in the consolidated balance sheets.

(d) Litigation

Various investigations, lawsuits, and claims arising in the normal course of operations are pending or on appeal against the Corporation. While the ultimate effect of such actions cannot be determined at this time, it is the opinion of management that the liabilities that may arise from such actions would not materially affect the consolidated financial position or results of operations of the Corporation.

(e) EHR Platform

The Corporation entered into an agreement with EPIC to deploy an integrated Electronic Health Record (EHR) with supporting revenue cycle, data analytics, and consumer-facing digital capabilities. When completed, this integration will, among other things, establish one EHR across all ambulatory sites to support the ability to manage physicians as one integrated practice and support the consolidation of the various revenue cycle systems to an integrated solution.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

The implementation will be done in phases. The first go-live was completed in May 2021. The anticipated completion date of the entire project is 2024. Through December 31, 2021, the Corporation has incurred approximately \$323,000 in capital and operating costs and anticipates spending an additional \$427,000 to complete the project.

(f) Other

Approximately 23% of the Corporation's employees were covered by collective bargaining agreements for the years ended December 31, 2021 and 2020, of which 12% expire in the next year.

(14) Functional Expenses

The Corporation provides general healthcare services primarily to residents within its geographic area and supports research and educational programs. Expenses are allocated based on estimated time and effort contingent upon the location and/or specialty the expense was incurred. Expenses related to providing these services and supporting functions are as follows for the years ended December 31, 2021 and 2020:

		2021	
	Healthcare services	General and administrative	Total
Salaries and wages \$	2,121,803	346,988	2,468,791
Physician fees and salaries	665,905	73,990	739,895
Employee benefits	435,083	70,828	505,911
Supplies	1,216,644	3,603	1,220,247
Other	948,989	298,564	1,247,553
Interest	87,403	13,580	100,983
Depreciation and amortization	227,647	43,377	271,024
Total \$	5,703,474	850,930	6,554,404

			2020	
	_	Healthcare services	General and administrative	Total
Salaries and wages	\$	1,907,440	325,252	2,232,692
Physician fees and salaries		540,334	60,037	600,371
Employee benefits		379,852	67,032	446,884
Supplies		1,085,520	1,099	1,086,619
Other		797,990	270,862	1,068,852
Interest		86,451	14,752	101,203
Depreciation and amortization	_	218,074	39,396	257,470
Total	\$_	5,015,661	778,430	5,794,091

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

(15) Investments in Joint Ventures

Corporation has invested in a number of joint ventures to provide specialty healthcare services. These services include surgical, diagnostic imaging, home care and hospice, rehabilitation, medical transportation and fitness, and wellness programs. The investments range from 25% to 53% ownership. The Corporation does not exercise operating control over these investments; accordingly, they are recorded under the equity method of accounting and report only the Corporation's share of net income attributable to the investee as equity in earnings in other revenue in the accompanying consolidated statements of operations. Financial information for the equity method investees for the years ended December 31, 2021 and 2020 includes net operating revenue of \$854,785 and \$554,891, net income of \$231,400 and \$136,987, and net income attributable to the Corporation of \$84,396 and \$50,967, respectively. For the year ended December 31, 2021, the Corporation invested capital of \$180,343 in joint ventures, of which \$152,005 of the investment related to joint ventures formed during 2021.

Total investments in joint ventures amounted to \$521,268 and \$319,948 at December 31, 2021 and 2020, respectively. These amounts are included in other assets, net in the consolidated balance sheets.

(16) Affiliation with Rutgers, The State University of New Jersey

The Corporation, Rutgers, the State University of New Jersey (Rutgers), and Rutgers Health Group (RHG) entered into a Master Affiliation Agreement (MAA) in 2018 to partner and create the state's largest academic healthcare system with the goal of integrating medical education, advanced research, and healthcare delivery to produce world class clinical services and outcomes.

The Corporation, Rutgers, and RHG are separate and distinct legal entities. The MAA requires reciprocal commitments and the alignment of each party's respective strategic, operational, and financial interests, and activities as part of a coordinated and mutually supportive academic health system. A Joint Committee was established for strategic planning and oversight featuring equal representation from the Corporation and Rutgers. The Corporation and Rutgers have continued to execute on strategies contemplated in the MAA including integrating the clinical operations of the Faculty of Robert Wood Johnson Medical School (RWJMS) and the Rutgers CINJ through Integrated Practice Agreements (IPA) effective July 1, 2020 and July 1, 2021, respectively. Under the terms of these agreements, Rutgers will continue to employ providers and certain support staff, but the Corporation will be responsible for the operations of the clinical practices and related financial results. This includes establishing a unified medical records system across the Corporation's entire medical group (including RWJMS and CINJ) and creating a unified and integrated patient experience.

The MAA required the Corporation to invest \$100,000 through June 30, 2019 of which \$45,000 was capitalized for the right to use the Rutgers Health brand name. In addition, more than \$1,000,000 over 20 years will be invested to expand the education and research mission of the integrated academic health system. During the years ended December 31, 2021 and 2020, the Corporation made payments to Rutgers in the amounts of \$60,963 and \$43,834, respectively, related to the MAA. As of December 31, 2021 and 2020, the Corporation owed Rutgers \$92,404 and \$58,808, net, respectively, under the MAA and IPA agreements. These amounts are included in accrued expenses and other liabilities in the consolidated balance sheets.

Notes to Consolidated Financial Statements

December 31, 2021 and 2020

(In thousands)

(17) Potential Affiliations

The Corporation and Saint Peter's Healthcare System (SPHCS) entered into a Definitive Agreement on September 10, 2020 to integrate the two healthcare systems. Under the terms of the Definitive Agreement, SPHCS, headquartered in New Brunswick, New Jersey, with its flagship hospital, Saint Peter's University Hospital, a 478-bed acute care teaching hospital and acute care children's hospital, will remain as a full-service provider of acute healthcare services, and would continue its mission and identity as a Catholic hospital in adherence with the standards of care stated in the Ethical and Religious Directives for Catholic Health Care Services. The Corporation has committed to making significant strategic capital investments in facilities, technology and innovation to enhance and expand clinical services provided at SPHCS.

Approvals will be necessary from state and federal officials, and others, before any of the transactions are considered complete. It is not currently possible to determine if, or when, the transactions will be completed.

(18) Subsequent Events

The Corporation, Trinitas Regional Medical Center (Trinitas) and Trinitas Health (TH) closed on their affiliation transaction, effective January 1, 2022, whereby the Corporation has replaced TH as the sole member of Trinitas. TH merged with, and into Trinitas, with Trinitas as the surviving merger entity. Trinitas is a 554-bed, Catholic, acute care teaching hospital, headquartered in Elizabeth, New Jersey. Under the terms of the Definitive Agreement, dated November 11, 2020, the role of Trinitas as a full service, Catholic provider of acute healthcare services for the eastern Union County community will be enhanced. Together, both organizations will be able to increase access to high-quality healthcare in the northern and central New Jersey regions, and expand outreach to underserved communities. This includes a specific focus on cardiac care, oncology, emergency services, renal care/dialysis, women's health and wound care, as well as behavioral health services and others.

On January 27, 2022, in connection with the Definitive Agreement, the Corporation legally defeased all of the outstanding New Jersey Health Care Facilities Financing Authority Refunding and Revenue Bonds, Trinitas Regional Medical Center Obligated Issue, Series 2016A and all of the outstanding New Jersey Health Care Facilities Financing Authority Refunding Bonds, Trinitas Regional Medical Center Obligated Issue, Series 2017A. The total payment for the defeased bonds was \$72,252.

Management evaluated all events occurring subsequent to December 31, 2021 and through April 27, 2022, the date the consolidated financial statements were available to be issued. The Corporation did not have any material recognizable subsequent events during the period, except as previously disclosed.

Consolidating Schedule - Balance Sheet Information

December 31, 2021

(In thousands)

Assets	Barnabas Health, Inc.	Children's Specialized Hospital	Clara Maass Medical Center	Community Medical Center	Jersey City Medical Center	Monmouth Medical Center	Newark Beth Israel Medical Center	Robert Wood Johnson University Hospital
Current assets:								
Cash and cash equivalents	\$ 214,753	1,077	6	10	16	11	363	859
Short-term investments	795,118	_	_	_	_	_	_	_
Assets limited or restricted as to use	54,940	4	_	_	66	_	_	5,559
Patient accounts receivable	_	12,481	26,894	44,278	41,866	56,500	61,757	205,567
Due from affiliates	85,798	90,547	89,255	386,117	142,304	650,929	408,462	1,400,666
Estimated amounts due from third-party payors	_	2,259	11,559	2,263	15,373	5,659	24,194	23,947
Other current assets	65,405	8,358	20,408	22,850	20,901	26,777	38,178	65,451
Total current assets	1,216,014	114,726	148,122	455,518	220,526	739,876	532,954	1,702,049
Assets limited or restricted as to use, noncurrent portion	514,776	3,576	2,864	2,873	2,142	5,658	31,856	12,766
Investments	4,785,674	_	_	_	_	_	1,153	140
Property, plant, and equipment, net	349,837	95,041	125,628	182,002	342,448	141,284	159,843	862,430
Right-of-use assets	51,621	5,373	442	11,038	46,450	3,000	3,469	43,678
Due from affiliates	19,051	_	_	_	_	_	_	_
Other assets, net	465,637	24,600	1,391	12,417	5,022	51,143	76	62,025
Total assets	\$ 7,402,610	243,316	278,447	663,848	616,588	940,961	729,351	2,683,088
Liabilities and Net Assets								
Current liabilities:								
Accounts payable	\$ 99,177	3,715	23,046	20,947	24,286	29,613	31,118	110,456
Accrued expenses and other current liabilities	233,591	17,375	27,713	37,406	48,447	66,301	94,423	216,943
Estimated amounts due to third-party payors	89	697	19,558	50,197	22,708	43,858	37,434	112,232
Long-term debt	2,568	1,017	2,316	1,358	1,538	3,474	4,776	12,694
Lease obligations	3,481	1,432	223	1,238	5,190	638	1,176	6,183
Due to affiliates	4,849,624	_	194	774	175	171,921	7	17,988
Self-insurance liabilities	41,434							
Total current liabilities	5,229,964	24,236	73,050	111,920	102,344	315,805	168,934	476,496
Estimated amounts due to third-party payors, net of current portion	_	_	3,210	17,434	6,654	2,785	14,682	7,946
Self-insurance liabilities, net of current portion	122,180	_	_	_	_	_	_	_
Long-term debt, less current portion	286,105	40,545	153,834	127,570	320,848	241,873	325,968	1,142,134
Lease obligations, less current portion	48,581	4,134	221	9,845	42,767	2,395	2,475	38,509
Accrued pension liability	29,018	_	_	_		_		
Other liabilities Due to affiliates	60,542	3,576	3,002	2,873	4,739	6,623	25,989	14,787
		19,051						
Total liabilities	5,776,390	91,542	233,317	269,642	477,352	569,481	538,048	1,679,872
Net assets	1,626,220	151,774	45,130	394,206	139,236	371,480	191,303	1,003,216
Total liabilities and net assets	\$ 7,402,610	243,316	278,447	663,848	616,588	940,961	729,351	2,683,088

Consolidating Schedule – Balance Sheet Information

December 31, 2021

(In thousands)

	Assets	_	Robert Wood Johnson University Hospital at Hamilton	Robert Wood Johnson University Hospital Rahway	Cooperman Barnabas Medical Center	Consolidating entries and eliminations	Total obligated group	Other entities	Consolidating entries and eliminations	Consolidated balance
Current asse	ts:									
	cash equivalents	\$	140	5	79	_	217,319	(63,224)	_	154,095
	n investments	•	_	_	_	_	795,118	(55,227)	(39,567)	755,551
Assets lim	ited or restricted as to use		167	284	_	_	61,020	29,585		90,605
Patient ac	counts receivable		16,832	14,443	112,428	_	593,046	85,691	_	678,737
Due from	affiliates		109,281	72,893	1,281,374	(4,659,925)	57,701	729,782	(787,483)	_
	amounts due from third-party payors		2,037	1,576	17,875	_	106,742	355	_	107,097
Other curr	ent assets	-	7,741	8,400	33,337		317,806	90,596	(33,599)	374,803
	Total current assets		136,198	97,601	1,445,093	(4,659,925)	2,148,752	872,785	(860,649)	2,160,888
Assets limite	d or restricted as to use, noncurrent portion		2,249	1,214	31,703	_	611,677	207,451	_	819,128
Investments			139	27	2,387	_	4,789,520	33,048	39,567	4,862,135
Property, pla	nt, and equipment, net		86,978	29,929	380,482	_	2,755,902	154,264	_	2,910,166
Right-of-use			5,092	411	12,005	_	182,579	75,510	_	258,089
Due from affi	······		_	_	_	(19,051)	_	14,813	(14,813)	_
Other assets	, net	-	2,869	902	5,841	(127,587)	504,336	312,418	(149,665)	667,089
	Total assets	\$_	233,525	130,084	1,877,511	(4,806,563)	10,992,766	1,670,289	(985,560)	11,677,495
	Liabilities and Net Assets									
Current liabili	ities:									
Accounts	• •	\$	15,687	14,587	60,542	_	433,174	59,057	_	492,231
	xpenses and other current liabilities		13,694	11,198	90,171	_	857,262	288,255	(29,332)	1,116,185
	amounts due to third-party payors		14,790	10,446	58,877	_	370,886	4,614		375,500
Long-term			1,647	122	10,914	_	42,424	310	(4,266)	38,468
Lease obli Due to affi	•		590 165	165 3	2,166 164	(4 650 025)	22,482	15,460 406,393	(707 402)	37,942
	ance liabilities		100	<u> </u>	104	(4,659,925)	381,090 41,434	406,393 59,128	(787,483)	100,562
Sell-IllSula	ance nabilities	-					41,434			
	Total current liabilities		46,573	36,521	222,834	(4,659,925)	2,148,752	833,217	(821,081)	2,160,888
	nounts due to third-party payors, net of current portion		1,156	5,937	2,320	_	62,124	_	_	62,124
	e liabilities, net of current portion					_	122,180	202,438		324,618
•	ebt, net of current portion		118,862	17,379	481,637	_	3,256,755	81,859	(10,679)	3,327,935
	tions, less current portion		4,535	250	10,221	_	163,933	70,500	_	234,433
Accrued pen						(0.507)	29,018	40.000	_	29,018
Other liabilitie Due to affiliat			2,471 —	752 —	8,861	(2,587)	131,628 14,813	18,302 —	(14,813)	149,930
Due to anilia		-			14,813	(19,051)				
Network	Total liabilities		173,597	60,839	740,686	(4,681,563)	5,929,203	1,206,316	(846,573)	6,288,946
Net assets		-	59,928	69,245	1,136,825	(125,000)	5,063,563	463,973	(138,987)	5,388,549
	Total liabilities and net assets	\$_	233,525	130,084	1,877,511	(4,806,563)	10,992,766	1,670,289	(985,560)	11,677,495

Consolidating Schedule – Balance Sheet Information

December 31, 2020

(In thousands)

Current assets:	Assets		Barnabas Health, Inc.	Children's Specialized Hospital	Clara Maass Medical Center	Community Medical Center	Jersey City Medical Center	Monmouth Medical Center	Newark Beth Israel Medical Center	Robert Wood Johnson University Hospital
Second sequelates	Current ecotor	_								
Second process Seco		•	170.057	005	6	10	16	25	630	2.040
Palest intended or restricted as to use 49,900 10 20,000 39,564 52,988 60,979 61,862 61,862 61,862 61,863 61,862 61,862 61,863	•	ф	- /							2,040
Palein accounts receivable										
Purpose Purp			49,590							-,
Character assets Ga21 R.349 7.401 7.3 5.899 9.907 8.372 4.534 7.000 7.00			66 556	, -			,	. ,		, .
Cher current assets 94,998 16,482 8,490 7,890 11,180 13,413 19,136 26,897 39,901										
Total current assets 940,398 105,445 192,207 465,322 177,601 736,005 461,201 1.196,316 Assets limited or restricted as to use, noncurrent portion 28,445 3,916 2,293 2,495 1,523 7,106 30,160 13,577 Property, plant, and equipment, net 276,467 74,647 74,64 129,143 164,142 31,2631 132,233 133,945 960,388 Due from affiliates 7,187 904 11,579 36,061 32,631 132,233 133,945 960,388 Due from affiliates 7,187 904 11,579 36,061 31,610 32,233 133,945 960,388 Due from affiliates 7,187 904 11,579 36,061 31,610 33,061 41,43 43,88 85,086 Due from affiliates 7,187 904 11,579 36,061 31,160 630,977 2,017,323 Total assets 8,670,601 21,388 32,573 653,045 535,061 31,160 630,977 2,017,323 Total assets 8,670,601 21,388 32,573 653,045 535,061 31,160 630,977 2,017,323 Current liabilities 8,670,601 21,388 32,573 34,552 53,122 54,571 81,054 Accrude expenses and other current liabilities 8,867,74 41,768 86,573 34,552 53,122 54,571 81,768 83,667 Accrude expenses and other current liabilities 8,867,74 41,768 86,573 34,552 53,122 54,571 81,768 83,667 Accrude expenses and other current liabilities 33,579 -							,			
Assets limited or restricted as to use, noncurrent portion 4,847 4,997 108 4,997 108 4,997 108 4,997 108 4,997 108		-								
Property plant, and equipment, net 4.97 74.664 129.143 164.142 312.631 132.233 133.945 698.348 180.045 11.579 38.051 4.143 4.368 50.368 1.00 11.579 38.051 4.143 4.368 50.368 1.00 11.579 38.051 4.143 4.368 50.368 1.00 11.579 1.00 11.579 1.00 1.0	Total current assets		940,398	105,445	•	465,322	1/7,601	736,005	461,201	1,196,316
Property, plant, and equipment, net \$276, 467 74,664 129,143 164,142 312,631 132,233 133,946 506,388 180,045 11,579 38,051 4,143 4,368 50,368 180,045 11,579 38,051 4,143 4,368 50,368 180,045 11,579 180,045 11,579 180,055 1	Assets limited or restricted as to use, noncurrent portion		-,	3,916	2,293	2,495	1,523	7,106		
Right of use assets S6,058 7,187 904 11,579 38,051 4,143 4,386 50,386 50.000 50.										
Due from affiliales				,						,
Current liabilities	· ·			•	904	•	•		•	50,366
Total assets \$ 6,709,601 217,388 325,731 653,045 535,061 931,160 630,977 2,017,323										
Current liabilities and Net Assets Sa,667 S,176 18,078 16,998 21,597 25,023 24,947 81,054 Accrued expenses and other current liabilities 212,574 14,768 68,573 34,552 53,122 54,571 81,796 183,657 25,023 24,947 81,054 25,025 25,575 25,5	Other assets, net	_	411,125	26,176	1,184	9,507	5,255	51,673	132	61,009
Current liabilities: \$ 83,667 5,176 18,078 16,998 21,597 25,023 24,947 81,054 16,0000	Total assets	\$_	6,709,601	217,388	325,731	653,045	535,061	931,160	630,977	2,017,323
Accounts payable \$ 83,667 5,176 18,078 16,998 21,597 25,023 24,947 81,054 Accrued expenses and other current liabilities 212,574 14,768 68,573 34,552 53,122 54,571 81,796 183,657 Estimated amounts due to third-party payors 89 — 10,644 31,398 8,343 19,427 19,639 59,118 Long-term debt 194 1,134 754 220 206 390 379 2,884 Lease obligations 4,333,419 — 5 19 128 161,724 59 503 Self-insurance liabilities 33,579 — <td< td=""><td>Liabilities and Net Assets</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	Liabilities and Net Assets									
Accounts payable \$ 83,667 5,176 18,078 16,998 21,597 25,023 24,947 81,054 Accrued expenses and other current liabilities 212,574 14,768 68,573 34,552 53,122 54,571 81,796 183,657 Estimated amounts due to third-party payors 89 — 10,644 31,398 8,343 19,427 19,639 59,118 Long-term debt 194 1,134 754 220 206 390 379 2,884 Lease obligations 4,333,419 — 5 19 128 161,724 59 503 Self-insurance liabilities 33,579 — <td< td=""><td>Current liabilities:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	Current liabilities:									
Accrued expenses and other current liabilities 212,574 14,768 68,573 34,552 53,122 54,571 81,796 183,657 Estimated amounts due to third-party payors 89 — 10,644 31,398 8,343 19,427 19,639 59,118 Long-term debt 1,134 754 220 206 390 379 2,884 Lease obligations 3,450 1,783 649 1,971 5,889 1,209 1,294 6,797 Due to affiliates 33,379 — — 5 19 128 161,724 59 503 Self-insurance liabilities 4,666,972 22,861 98,703 85,158 89,285 262,44 128,114 334,013 Estimated amounts due to third-party payors, net of current portion — </td <td></td> <td>\$</td> <td>83.667</td> <td>5.176</td> <td>18.078</td> <td>16.998</td> <td>21.597</td> <td>25.023</td> <td>24.947</td> <td>81.054</td>		\$	83.667	5.176	18.078	16.998	21.597	25.023	24.947	81.054
Long-term debt 194 1,134 754 220 206 390 379 2,884 Lease obligations 3,450 1,783 649 1,971 5,889 1,209 1,294 6,797 Due to affiliates 4,333,419 — 5 19 128 161,724 59 503 Self-insurance liabilities 33,579 — <	• •			,						,
Long-term debt 194 1,134 754 220 206 390 379 2,884 Lease obligations 3,450 1,783 649 1,971 5,889 1,209 1,294 6,797 Due to affiliates 4,333,419 — 5 19 128 161,724 59 50 Self-insurance liabilities 4,666,972 22,861 98,703 85,158 89,285 262,344 128,114 334,013 Estimated amounts due to third-party payors, net of current portion — — — 20,360 56,585 27,351 42,556 45,490 114,241 Self-insurance liabilities, net of current portion —	Estimated amounts due to third-party payors		89	_	10,644	31,398	8,343	19,427	19,639	59,118
Due to affiliates 4,333,419 or 33,679 5 19 or 128 or 128 or 161,724 or 161,72			194	1,134	754	220	206	390	379	2,884
Self-insurance liabilities 33,579 — <t< td=""><td>Lease obligations</td><td></td><td>3,450</td><td>1,783</td><td>649</td><td>1,971</td><td>5,889</td><td>1,209</td><td>1,294</td><td>6,797</td></t<>	Lease obligations		3,450	1,783	649	1,971	5,889	1,209	1,294	6,797
Total current liabilities	Due to affiliates		4,333,419	_	5	19	128	161,724	59	503
Estimated amounts due to third-party payors, net of current portion 100,195	Self-insurance liabilities	=	33,579							
Self-insurance liabilities, net of current portion 100,195 —	Total current liabilities		4,666,972	22,861	98,703	85,158	89,285	262,344	128,114	334,013
Long-term debt, less current portion 306,791 41,756 160,445 101,583 224,447 249,222 238,529 612,455 Lease obligations, less current portion 50,925 5,566 258 9,575 32,550 2,929 3,241 44,185 Accrued pension liability 31,465 — <t< td=""><td>Estimated amounts due to third-party payors, net of current portion</td><td></td><td>_</td><td>_</td><td>20,360</td><td>56,585</td><td>27,351</td><td>42,556</td><td>45,490</td><td>114,241</td></t<>	Estimated amounts due to third-party payors, net of current portion		_	_	20,360	56,585	27,351	42,556	45,490	114,241
Lease obligations, less current portion 50,925 5,566 258 9,575 32,550 2,929 3,241 44,185 Accrued pension liability 31,465 — <td>Self-insurance liabilities, net of current portion</td> <td></td> <td>100,195</td> <td>_</td> <td>_</td> <td>_</td> <td>_</td> <td></td> <td>_</td> <td>_</td>	Self-insurance liabilities, net of current portion		100,195	_	_	_	_		_	_
Accrued pension liability 31,465 — <th< td=""><td>Long-term debt, less current portion</td><td></td><td>,</td><td></td><td></td><td></td><td></td><td></td><td></td><td>612,455</td></th<>	Long-term debt, less current portion		,							612,455
Other liabilities Due to affiliates 56,443 bus to affiliates 3,948 bus to affiliates 4,869 bus to affiliates 5,792 bus to affiliates 7,525 bus to affiliates 11,283 bus to affiliates 25,995 bus to affiliates Total liabilities 5,212,791 bus to affiliates 74,131 bus to affiliates 258,693 bus to affiliates 381,158 bus to affiliates 568,334 bus to affiliates 443,976 bus to affiliates Net assets 1,496,810 bus to affiliate affiliates 143,257 bus to affiliate affiliates 394,352 bus to affiliate affiliates 153,903 bus to affiliate affiliates 187,001 bus to affiliates				5,566	258	9,575	32,550	2,929	3,241	44,185
Due to affiliates —	•									
Total liabilities 5,212,791 74,131 284,635 258,693 381,158 568,334 443,976 1,130,889 Net assets 1,496,810 143,257 41,096 394,352 153,903 362,826 187,001 886,434				•			•		•	•
Net assets 1,496,810 143,257 41,096 394,352 153,903 362,826 187,001 886,434	Due to affiliates	-								
	Total liabilities		5,212,791	74,131	284,635	258,693	381,158	568,334	443,976	1,130,889
Total liabilities and net assets \$ 6,709,601 217,388 325,731 653,045 535,061 931,160 630,977 2,017,323	Net assets	-	1,496,810	143,257	41,096	394,352	153,903	362,826	187,001	886,434
	Total liabilities and net assets	\$ <u></u>	6,709,601	217,388	325,731	653,045	535,061	931,160	630,977	2,017,323

Consolidating Schedule – Balance Sheet Information

December 31, 2020

(In thousands)

Assets	_	Robert Wood Johnson University Hospital at Hamilton	Robert Wood Johnson University Hospital Rahway	Cooperman Barnabas Medical Center	Consolidating entries and eliminations	Total obligated group	Other entities	Consolidating entries and eliminations	Consolidated balance
Current assets:									
Cash and cash equivalents	\$	66	1,455	129	_	185,327	(84,947)	_	100,380
Short-term investments Assets limited or restricted as to use		— 161	 215	_	_	578,074 55,604	86.999	_	578,074 142,603
Patient accounts receivable		15,473	11,881	96,206	_	527,453	61,771	_	589,224
Due from affiliates		126,229	77,211	1,272,685	(4,257,006)	48,971	594,283	(643,254)	
Estimated amounts due from third-party payors		247	· —	72	_	31,022	_	_	31,022
Other current assets	_	5,794	3,856	21,630		224,348	42,983	(28,707)	238,624
Total current assets		147,970	94,618	1,390,722	(4,257,006)	1,650,799	701,089	(671,961)	1,679,927
Assets limited or restricted as to use, noncurrent portion		1,884	965	31,192	_	123,550	150,352	_	273,902
Investments		156	18	3,194	_	5,001,320	31,186	_	5,032,506
Property, plant, and equipment, net		90,008	32,945	385,628	_	2,428,194	135,215	_	2,563,409
Right-of-use assets		5,899	762	12,151	_	191,468	78,195		269,663
Due from affiliates Other assets, net		2.809	— 863	5,788	— (127,650)	— 447,871	19,813 152,646	(19,813) (143,017)	457,500
	-	,,,,,,							
Total assets	\$_	248,726	130,171	1,828,675	(4,384,656)	9,843,202	1,268,496	(834,791)	10,276,907
Liabilities and Net Assets									
Current liabilities:									
Accounts payable	\$	12,333	11,986	46,958	_	347,817	40,553	_	388,370
Accrued expenses and other current liabilities		11,687	11,749	76,664	_	803,713	169,038	(23,518)	949,233
Estimated amounts due to third-party payors		8,173	4,526	31,825	_	193,182	14,750	(0.000)	207,932
Long-term debt Lease obligations		1,303 831	74 352	5,333 2,543	_	12,871 26,768	239 15,469	(3,886)	9,224 42,237
Due to affiliates		22	352 19	2,543 614	(4,257,006)	239,506	403,748	(643,254)	42,237
Self-insurance liabilities		_	—	-	(4,237,000)	33,579	49,352	(043,234)	82,931
Total current liabilities	-	34,349	28,706	163,937	(4,257,006)	1,657,436	693,149	(670,658)	1,679,927
Estimated amounts due to third-party payors, net of current portion		14,147	16,083	63,225	_	400,038	512	_	400,550
Self-insurance liabilities, net of current portion				-	_	100,195	165,745	_	265,940
Long-term debt, net of current portion		120,995	13,841	455,012	_	2,525,076	82,273	(14,946)	2,592,403
Lease obligations, less current portion		5,027	413	9,922	_	164,591	72,455	`	237,046
Accrued pension liability		_	_	_	_	31,465	_	_	31,465
Other liabilities		3,704	1,530	15,152	(2,650)	162,193	47,955	_	210,148
Due to affiliates	-			19,813		19,813		(19,813)	
Total liabilities		178,222	60,573	727,061	(4,259,656)	5,060,807	1,062,089	(705,417)	5,417,479
Net assets	_	70,504	69,598	1,101,614	(125,000)	4,782,395	206,407	(129,374)	4,859,428
Total liabilities and net assets	\$_	248,726	130,171	1,828,675	(4,384,656)	9,843,202	1,268,496	(834,791)	10,276,907

Consolidating Schedule – Statement of Operations and Changes in Net Assets Information

Year ended December 31, 2021

(In thousands)

Patient service revenue		_	Barnabas Health, Inc.	Children's Specialized Hospital	Clara Maass Medical Center	Community Medical Center	Jersey City Medical Center	Monmouth Medical Center	Newark Beth Israel Medical Center	Robert Wood Johnson University Hospital
CARES Act grant reverue 2.537 949 2.501 3.455 4.302 30,019 115 Other revenue, net 1.047,141 22.674 26.362 13.612 28.166 30.568 56.023 62.021 Total revenue 1.047,141 169.848 347,114 459,319 444,940 60.000 693,387 1,708,040 Expenses: 222.658 87,165 133,464 172,611 160.23 215,044 223,493 568,099 Physician fees and salaries 222,658 87,1655 133,464 172,611 160.23 215,044 223,493 568,699 Employee benefits 366,769 22.291 27,102 31,493 31,565 37,607 61,678 87,695 Supplies 5,575 5,458 54,170 87,204 69,028 103,602 11,983 355,64 Other 133,454 43,142 24,029 13,562 13,562 12,648 Other 14,024 24,533 67,05 13,823 16,712<	Revenue:									
Other revenue, nef 1,047,141 22,674 26,362 13,812 28,126 30,568 58,023 62,021 Total revenue 1,047,141 169,848 347,114 459,319 444,940 600,000 693,387 1,708,040 Expensers 87,658 87,165 133,464 172,611 160,293 215,204 233,493 563,999 Physician fees and vages 222,658 87,165 133,464 172,611 160,293 215,204 233,493 186,684 Employee benefits 366,769 22,919 27,102 31,4364 172,611 69,028 103,629 119,818 382,568 Employee benefits 35,575 5,458 64,170 87,204 69,028 103,629 119,818 392,584 Other 0th 335,393 24,71 87,755 117,929 105,000 60,452 99,977 89,929 25,489 Other, certain and amortization 32,563 6,705 6,095 3,864 60,512 604,522 609,511	Patient service revenue	\$	_			443,206	413,359	565,130	605,345	1,645,904
Total revenue 1,047,141 169,848 347,114 459,319 444,940 600,000 693,387 1,708,040	CARES Act grant revenue		_			2,501	3,455			
Expenses: Salaries and wages 222,658 87,165 133,464 172,611 160,293 215,204 223,493 563,999 224,000 10,868 21,545 33,685 56,515 57,692 87,994 186,684 223,493 31,555 37,607 61,878 87,695 39,6769 22,291 27,102 31,493 31,555 37,607 61,878 87,695 33,695 33,695 34,707 31,493 31,555 37,607 61,878 87,695 33	Other revenue, net	_	1,047,141	22,674	26,362	13,612	28,126	30,568	58,023	62,021
Salaries and wages 222,658 87,165 133,464 172,611 160,293 215,204 223,493 563,999 Physician fees and salaries — 10,886 21,545 33,685 56,515 57,692 87,984 186,884 Employee benefits 396,769 22,291 27,102 31,493 31,665 37,607 61,678 87,085 Supplies 5,575 5,458 54,170 87,204 69,028 103,629 119,881 392,564 Other 336,390 29,471 87,775 117,992 100,509 160,017 189,993 25,689 Interest 11,444 2,465 6,095 3,864 9,492 9,377 8,929 25,489 Depreciation and amortization 32,563 6,705 13,823 16,712 24,029 21,016 18,359 72,794 Total expenses 1,005,399 164,441 343,974 463,561 460,512 600,512 8,681,71 Income (loss) from operations 41,742 5,407	Total revenue	_	1,047,141	169,848	347,114	459,319	444,940	600,000	693,387	1,708,040
Physician fees and salaries	Expenses:									
Employee benefits 396,769 22,291 27,102 31,493 31,565 37,607 61,878 87,695 Supplies 5,575 5,458 54,170 87,705 117,992 109,590 119,881 392,564 Other 336,390 29,471 87,775 117,992 109,590 160,017 169,993 355,646 Incest 11,444 2,465 6,095 3,864 9,492 9,377 8,929 25,489 Perciation and amortization 32,563 6,705 13,823 16,712 24,029 21,016 18,359 72,794 Income (loss) from operations 41,742 5,407 3,140 46,3561 460,512 604,542 690,517 1,684,871 Income (loss) from operations 41,742 5,407 3,140 4,242 (15,572) 46,542 690,517 1,684,871 Income (loss) from operating revenue (expenses), net 343,832 — — — — — 1,156 (17,41 7,160 1,162 1,162<	Salaries and wages		222,658	,	,	,	,	,	,	,
Supplies 5,675 5,458 54,170 87,204 69,028 103,629 119,881 392,684 Other 336,390 29,471 87,775 117,992 109,590 160,017 169,993 355,648 Interest 11,444 2,465 6,095 3,864 9,492 9,377 8,992 25,489 Depreciation and amortization 32,563 6,705 13,823 16,712 24,029 21,016 18,359 72,794 Total expenses 1,005,399 164,441 343,974 463,561 460,512 604,542 690,517 1,684,871 Income (loss) from operations 41,742 5,407 3,140 (4,242) (15,572) (4,542) 2,870 23,169 Nonoperating revenue (expenses), net: 343,832 — — — — — (15,572) (4,542) (15,572) (4,542) (4,542) (4,542) (4,542) (4,542) (4,542) (4,542) (4,542) (4,542) (4,542) (4,542) (4,542)	,		_	,	,	,	,	,	,	,
Other Interest I	• •			,	,	,	,	,	,	,
Interest 11,444 2,465 6,095 3,864 9,492 9,377 8,929 25,489 1,005 32,563 3,253 16,712 24,029 21,016 18,359 72,794 1,005,399 164,441 343,974 463,561 460,512 604,542 690,517 1,684,871 1,000	• •		,	,	,	,		,	,	,
Depreciation and amortization 32,563 6,705 13,823 16,712 24,029 21,016 18,359 72,794 Total expenses 1,005,399 164,441 343,974 463,561 460,512 604,542 690,517 1,684,871 Income (loss) from operations 41,742 5,407 3,140 (4,242) (15,572) (4,542) 2,870 23,169 Nonoperating revenue (expenses), net: 343,832 — — — — — — (15,572) (15,572) (15,572) (15,572) (15,572) 2,370 23,169 Other, net 343,832 — — — — — — (155) (238) (177) Total nonoperating revenue (expenses), net 345,392 — (108) (345) (194) (155) (238) (177) Total onoperating revenue (expenses), net 387,134 5,407 3,032 (4,587) (15,66) (4,697) 2,478 23,738 Pension changes other than net periodic benefit cost 471 </td <td></td> <td></td> <td></td> <td></td> <td>- , -</td> <td></td> <td>,</td> <td></td> <td>,</td> <td>,</td>					- , -		,		,	,
Total expenses 1,005,399 164,441 343,974 463,561 460,512 604,542 690,517 1,684,871 Income (loss) from operations 41,742 5,407 3,140 (4,242) (15,572) (4,542) 2,870 23,169 Nonoperating revenue (expenses), net: Investment income (loss), net 343,832					,			,		
Nonoperating revenue (expenses), net 1,560	Depreciation and amortization	_	32,563	6,705	13,823	16,712	24,029	21,016	18,359	72,794
Nonoperating revenue (expenses), net: Investment income (loss), net Other, net Total nonoperating revenue (expenses), net Excess (deficiency) of revenue over expenses 345,392	Total expenses	_	1,005,399	164,441	343,974	463,561	460,512	604,542	690,517	1,684,871
Investment income (loss), net 343,832	Income (loss) from operations	_	41,742	5,407	3,140	(4,242)	(15,572)	(4,542)	2,870	23,169
Excess (deficiency) of revenue over expenses 387,134 5,407 3,032 (4,587) (15,766) (4,697) 2,478 23,738 Pension changes other than net periodic benefit cost 471 — <td>Investment income (loss), net</td> <td>_</td> <td></td> <td></td> <td> (108)</td> <td>(345)</td> <td>— (194)</td> <td><u> </u></td> <td></td> <td></td>	Investment income (loss), net	_			 (108)	(345)	— (194)	<u> </u>		
Pension changes other than net periodic benefit cost 471 — — — — — — — — — — — — — — — — — — —	Total nonoperating revenue (expenses), net		345,392		(108)	(345)	(194)	(155)	(392)	569
Net assets released from restriction for purchases of property and equipment Other, net — 657 (258,195) 937 (1,273) 1,273 (1,119) 3,471 (2,021) 813 (2,021) 5,281 (2,021) 90,273 (2,021)	Excess (deficiency) of revenue over expenses	_	387,134	5,407	3,032	(4,587)	(15,766)	(4,697)	2,478	23,738
Other, net (258,195) — (146) 164 140 2,021 1,217 90,273 Total other changes in net assets (257,724) 657 791 1,437 1,259 5,492 2,030 95,554 Increase (decrease) in net assets without donor restrictions 129,410 6,064 3,823 (3,150) (14,507) 795 4,508 119,292 Change in net assets with donor restrictions — 2,453 211 3,004 (160) 7,859 (206) (2,510) Net assets, beginning of year 1,496,810 143,257 41,096 394,352 153,903 362,826 187,001 886,434	Pension changes other than net periodic benefit cost		471	_	_	_	_	_	_	_
Increase (decrease) in net assets without donor restrictions 129,410 6,064 3,823 (3,150) (14,507) 795 4,508 119,292 Change in net assets with donor restrictions — 2,453 211 3,004 (160) 7,859 (206) (2,510) Net assets, beginning of year 1,496,810 143,257 41,096 394,352 153,903 362,826 187,001 886,434			— (258,195)							
Change in net assets with donor restrictions — 2,453 211 3,004 (160) 7,859 (206) (2,510) Net assets, beginning of year 1,496,810 143,257 41,096 394,352 153,903 362,826 187,001 886,434	Total other changes in net assets		(257,724)	657	791	1,437	1,259	5,492	2,030	95,554
Net assets, beginning of year 1,496,810 143,257 41,096 394,352 153,903 362,826 187,001 886,434	Increase (decrease) in net assets without donor restrictions		129,410	6,064	3,823	(3,150)	(14,507)	795	4,508	119,292
Net assets, end of year \$ 1,626,220	•	_	 1,496,810							
	Net assets, end of year	\$	1,626,220	151,774	45,130	394,206	139,236	371,480	191,303	1,003,216

Consolidating Schedule – Statement of Operations and Changes in Net Assets Information

Year ended December 31, 2021

(In thousands)

	_	Robert Wood Johnson University Hospital at Hamilton	Robert Wood Johnson University Hospital Rahway	Cooperman Barnabas Medical Center	Consolidating entries and eliminations	Total obligated group	Other entities	Consolidating entries and eliminations	Consolidated balance
Revenue: Patient service revenue CARES Act grant revenue Other revenue, net	\$	190,923 7,442 5,094	119,043 8,334 10,016	1,002,602 5,279 28,196	 (970,163)	5,449,952 64,933 361,670	627,922 177 521,159	— — (399,290)	6,077,874 65,110 483,539
Total revenue	_	203,459	137,393	1,036,077	(970,163)	5,876,555	1,149,258	(399,290)	6,626,523
Expenses: Salaries and wages Physician fees and salaries Employee benefits Supplies Other Interest Depreciation and amortization	_	76,511 16,420 10,964 43,236 55,089 4,319 9,373	55,536 13,732 8,706 21,917 32,982 549 4,793	288,449 103,386 60,665 223,387 280,642 18,667 35,529	(313,198) — (656,030) (935)	2,199,383 588,529 463,537 1,126,049 1,079,557 99,755 255,696	269,408 401,943 79,133 97,839 274,151 3,386 15,328	(250,577) (36,759) (3,641) (106,155) (2,158)	2,468,791 739,895 505,911 1,220,247 1,247,553 100,983 271,024
Total expenses	_	215,912	138,215	1,010,725	(970,163)	5,812,506	1,141,188	(399,290)	6,554,404
Income (loss) from operations	_	(12,453)	(822)	25,352		64,049	8,070		72,119
Nonoperating revenue (expenses), net: Investment income (loss), net Other, net Total nonoperating revenue (expenses), net	<u>-</u>	(7) — (7)	7 (216) (209)	(299) (178) (477)		344,125 (51) 344,074	2,574 (1,651) 923		346,699 (1,702) 344,997
Excess (deficiency) of revenue over expenses		(12,460)	(1,031)	24,875		408,123	8,993		417,116
Pension changes other than net periodic benefit cost Net assets released from restriction for purchases of property and equipme Other, net	ent _	1,824	176 300	5,767 7,467		471 19,494 (154,935)	160,307	— — (942)	471 19,494 4,430
Total other changes in net assets	_	1,824	476	13,234		(134,970)	160,307	(942)	24,395
Increase (decrease) in net assets without donor restrictions		(10,636)	(555)	38,109	_	273,153	169,300	(942)	441,511
Change in net assets with donor restrictions Net assets, beginning of year	_	60 70,504	202 69,598	(2,898) 1,101,614	(125,000)	8,015 4,782,395	88,266 206,407	(8,671) (129,374)	87,610 4,859,428
Net assets, end of year	\$_	59,928	69,245	1,136,825	(125,000)	5,063,563	463,973	(138,987)	5,388,549

Consolidating Schedule – Statement of Operations and Changes in Net Assets Information

Year ended December 31, 2020

(In thousands)

Patient service revenue		_	Barnabas Health, Inc.	Children's Specialized Hospital	Clara Maass Medical Center	Community Medical Center	Jersey City Medical Center	Monmouth Medical Center	Newark Beth Israel Medical Center	Robert Wood Johnson University Hospital
CARES Act grant revenue — 5.418 billion 20.356 billion 44.769 billion 57.538 billion 81,444 billion 131,860 billion Chare revenue, net venue 944,000 18.670 billion 53.88 billion 2.541 billion 18.699 billion 17.588 billion 83,688 billion 44,986 billion 18.699 billion 17.588 billion 93,688 billion 44,986 billion 413,561 billion 573,050 billion 643,759 billion 15.51,42 Expensers 208,449 billion 82,549 billion 125,784 billion 117,688 billion 55,013 billion 525,888 billion 525,888 billion 87,474 billion 54,753 billion 55,013 billion 525,888 billion 87,262 billion 152,217 billion 55,013 billion 525,888 billion 55,888 billion 67,474 billion 54,753 billion 55,013 billion 525,888 billion 55,888 billion 67,474 billion 54,753 billion 55,013 billion 525,888 billion 152,217 billion 62,011 billion 60,013 billion 60,012 billion 40,013 billion 40,038 billion 40,038 billion 40,038 billion 152,217 billion 52,617 billion 62,618 billion	Revenue:									
Other revenue, net 944,000 18,670 5,388 2,541 18,699 17,598 39,608 44,986 Total revenue 944,125 159,878 286,687 412,938 413,561 573,050 643,759 1,545,142 Expenses: 8 82,549 125,784 147,698 151,426 200,753 213,189 525,868 Physician fees and salaries 22,661 10,792 21,388 27,474 54,753 55,013 87,262 152,217 Employee benefits 324,625 19,057 26,711 30,037 30,935 36,707 59,012 85,132 Supplies 33,044 51,35 46,891 77,031 63,132 98,518 104,384 335,146 Other Chiper 318,515 26,557 74,649 106,754 90,295 135,188 143,257 312,753 Depreciation and amortization 25,381 525,683 13,404 15,308 20,668 20,967 17,242 71,942 Depreciation and parti		\$	125	135,790	260,943	365,628	344,108	497,914	522,707	1,368,296
Total revenue 944,125 159,878 286,687 412,938 413,561 573,050 643,759 1,545,142 Expenses: Salaries and wages 208,449 82,549 125,784 147,698 151,426 200,753 213,189 525,688 Physician fees and salaries 22,661 10,792 21,368 27,474 54,753 55,013 87,262 152,217 Employee benefits 324,625 19,057 26,711 30,037 30,935 36,707 59,012 85,132 Supplies 318,515 26,557 74,649 106,754 90,285 135,188 104,384 335,146 Other 318,515 26,557 74,649 106,754 90,285 135,188 143,257 312,753 Interest 11,676 1,617 6,218 3,820 9,451 9,497 9,062 25,232 Expension and amortization 29,315 6,936 13,404 15,308 20,668 20,967 17,242 71,942 Total expenses 918,545 152,643 315,025 408,122 420,660 556,643 633,408 1,508,290 Income (loss) from operations 25,580 7,235 (28,38) 4,816 (7,099 16,407 10,351 36,852 Nonoperating revenue (expenses), net 793,683 -	CARES Act grant revenue		_	5,418	20,356	44,769	50,754	57,538	81,444	131,860
Expenses: Salaries and wages 208,449 82,549 125,784 147,698 151,426 200,753 213,189 525,868 Physician fees and salaries 22,661 10,792 21,368 27,474 54,753 55,013 213,189 525,868 Physician fees and salaries 324,625 19,057 26,711 30,037 30,935 36,707 59,012 85,132 Employee benefits 33,04 5,135 46,891 77,031 63,132 98,518 104,384 335,146 Other 318,515 26,557 74,649 106,754 90,295 135,188 143,257 312,753 Interest 11,676 1,617 6,218 3,820 9,451 9,497 9,062 25,232 Depreciation and amortization 29,315 6,936 13,404 15,308 20,668 20,967 17,242 71,942 Income (loss) from operations 25,580 7,235 (28,338) 4,816 (7,099) 16,407 10,351 36,852	Other revenue, net	_	944,000	18,670	5,388	2,541	18,699	17,598	39,608	44,986
Salaries and wages 208,449 82,549 125,784 147,698 151,426 200,753 213,189 525,808 Physician fees and salaries 22,661 10,792 21,368 27,474 54,753 55,013 87,262 152,217 Employee benefits 324,625 19,057 26,711 30,037 30,935 36,707 59,012 85,132 Supplies 3,304 5,135 46,891 77,031 63,132 98,518 104,384 335,146 Other 318,515 26,557 74,649 106,754 90,295 135,188 143,257 312,753 Interest 11,676 1,617 6,218 3,820 9,451 9,497 9,062 25,232 Depreciation and amortization 29,315 6,936 13,404 15,308 20,668 20,967 17,242 71,942 Income (loss) from operations 25,580 7,235 (28,338) 4,816 (7,099) 16,407 10,351 36,852 Nonoperating revenue (expenses), net:	Total revenue	_	944,125	159,878	286,687	412,938	413,561	573,050	643,759	1,545,142
Physician fees and salaries 22,661 10,792 21,368 27,474 54,753 55,013 87,262 152,217 Employee benefits 324,625 19,057 26,711 30,037 30,935 36,707 59,012 85,132 Supplies 33,04 5,155 46,891 77,031 63,132 98,518 104,384 335,146 Other 11,676 1,617 6,218 3,820 9,451 9,497 9,062 25,232 Depreciation and amortization 29,315 6,936 13,404 15,308 20,668 20,967 17,242 71,942 Total expenses 918,545 152,643 315,025 408,122 420,660 556,643 633,408 1,508,290 Income (loss) from operations 25,580 7,235 (28,338) 4,816 (7,099) 16,407 10,351 36,852 Nonoperating revenue (expenses), net: 1,000 4,253 - - - - - - - - - -	Expenses:									
Employee benefits 324,625 19,057 26,711 30,037 30,935 36,707 59,012 85,132 Supplies 3,304 5,135 46,891 77,031 63,132 98,518 104,384 335,146 Other 318,515 26,557 74,649 106,754 90,295 135,188 143,257 312,753 Interest 11,676 1,617 6,218 3,820 9,451 9,497 9,062 25,232 Depreciation and amortization 29,315 6,936 13,404 15,308 20,668 20,967 17,242 71,942 Total expenses 918,545 152,643 315,025 408,122 420,660 556,643 633,408 1,508,290 Income (loss) from operations 25,580 7,235 (28,338) 4,816 (7,099) 16,407 10,351 36,852 Nonoperating revenue (expenses), net: 1,000 4,253 — — — — — — — 16 (6) Other,	Salaries and wages		208,449	82,549	125,784	147,698	151,426	200,753	213,189	525,868
Supplies 3,304 5,135 46,891 77,031 63,132 98,518 104,384 335,146 Other 318,515 26,557 74,649 106,754 90,251 135,188 143,257 312,753 Interest 11,676 1,617 6,218 3,820 9,451 9,497 9,062 25,232 Depreciation and amortization 29,315 6,936 13,404 15,308 20,668 20,967 17,242 71,942 Total expenses 918,545 152,643 315,025 408,122 420,660 556,643 633,408 1,508,290 Income (loss) from operations 25,580 7,235 (28,338) 4,816 (7,099) 16,407 10,351 36,852 Nonoperating revenue (expenses), net: 1nvestment income (loss), net 793,683 — — — — — — — 16 (6) Other, net 793,683 — — — — — — — — — — </td <td>Physician fees and salaries</td> <td></td> <td>22,661</td> <td>10,792</td> <td>21,368</td> <td>27,474</td> <td>54,753</td> <td>55,013</td> <td>87,262</td> <td>152,217</td>	Physician fees and salaries		22,661	10,792	21,368	27,474	54,753	55,013	87,262	152,217
Other Interest Interest Interest Investment income (loss), net Cyter, net 318,515 1,626 1,637 1,638 1,637 1,638 1,637 1,638 1,63	Employee benefits		324,625	19,057	26,711	30,037	30,935	36,707	59,012	85,132
Interest 11,676 1,617 6,218 3,820 9,451 9,497 9,062 25,232 29,315 6,936 13,404 15,308 20,668 20,967 17,242 71,942	Supplies		3,304	5,135	46,891	77,031	63,132	98,518	104,384	335,146
Depreciation and amortization 29,315 6,936 13,404 15,308 20,668 20,967 17,242 71,942 Total expenses 918,545 152,643 315,025 408,122 420,660 556,643 633,408 1,508,290 Income (loss) from operations 25,580 7,235 (28,338) 4,816 (7,099) 16,407 10,351 36,852 Nonoperating revenue (expenses), net: 879,3683 - - - - - - - - - - - - 16 (6) (6) (00 (00 (436) (226) (354) (454) (207) (207) (436) (226) (354) (438) (213) (207) (203) (436) (226) (354) (438) (213) (200) (436) (226) (354) (438) (213) (200) (200) (436) (226) (354) (438) (213) (200) (200) (200) (200) (200) (200)	Other		318,515	26,557	74,649	106,754	90,295	135,188	143,257	312,753
Total expenses 918,545 152,643 315,025 408,122 420,660 556,643 633,408 1,508,290	Interest		11,676	1,617	6,218	3,820	9,451	9,497	9,062	25,232
Nonoperating revenue (expenses), net: Investment income (loss), net (expenses), net: Investment income (loss), net (expenses), net (expe	Depreciation and amortization	_	29,315	6,936	13,404	15,308	20,668	20,967	17,242	71,942
Nonoperating revenue (expenses), net: Investment income (loss), net Other, net Total nonoperating revenue (expenses), net Excess (deficiency) of revenue over expenses 823,516 7,235 Pension changes other than net periodic benefit cost Net assets released from restriction for purchases of property and equipment Net assets transferred Other, net Nonoperating revenue (expenses), net 793,683 -	Total expenses		918,545	152,643	315,025	408,122	420,660	556,643	633,408	1,508,290
Investment income (loss), net 793,683 16 (6)	Income (loss) from operations	_	25,580	7,235	(28,338)	4,816	(7,099)	16,407	10,351	36,852
Excess (deficiency) of revenue over expenses 823,516 7,235 (28,541) 4,380 (7,325) 16,053 9,913 36,639 Pension changes other than net periodic benefit cost (11,282) —	Investment income (loss), net	_	,			— (436)	— (226)	(354)		
Pension changes other than net periodic benefit cost (11,282) —<	Total nonoperating revenue (expenses), net	_	797,936		(203)	(436)	(226)	(354)	(438)	(213)
Net assets released from restriction for purchases of property and equipment — 1,493 780 2,191 936 1,246 1,754 5,046 Net assets transferred 9,668 — <td< td=""><td>Excess (deficiency) of revenue over expenses</td><td>_</td><td>823,516</td><td>7,235</td><td>(28,541)</td><td>4,380</td><td>(7,325)</td><td>16,053</td><td>9,913</td><td>36,639</td></td<>	Excess (deficiency) of revenue over expenses	_	823,516	7,235	(28,541)	4,380	(7,325)	16,053	9,913	36,639
Total other changes in net assets (58.577) 1.263 608 3.848 19.979 2.666 4.173 19.034	Net assets released from restriction for purchases of property and equipment Net assets transferred		9,668	1,493 —	780 —	2,191 —	936 —	1,246 —	1,754 —	· -
(00,011) 1,200 000 0,010 10,010 2,000 4,110 10,004	Total other changes in net assets	_	(58,577)	1,263	608	3,848	19,979	2,666	4,173	19,034
Increase (decrease) in net assets without donor restrictions 764,939 8,498 (27,933) 8,228 12,654 18,719 14,086 55,673	Increase (decrease) in net assets without donor restrictions		764,939	8,498	(27,933)	8,228	12,654	18,719	14,086	55,673
Change in net assets with donor restrictions — 5,264 115 (214) 2,634 4,895 (1,362) (6,114) Net assets, beginning of year 731,871 129,495 68,914 386,338 138,615 339,212 174,277 836,875	•	_	— 731,871	,			,			
Net assets, end of year \$ 1,496,810 143,257 41,096 394,352 153,903 362,826 187,001 886,434	Net assets, end of year	\$	1,496,810	143,257	41,096	394,352	153,903	362,826	187,001	886,434

Consolidating Schedule – Statement of Operations and Changes in Net Assets Information

Year ended December 31, 2020

(In thousands)

		Robert Wood Johnson University Hospital at Hamilton	Robert Wood Johnson University Hospital Rahway	Cooperman Barnabas Medical Center	Consolidating entries and eliminations	Total obligated group	Other entities	Consolidating entries and eliminations	Consolidated balance
Revenue:									
Patient service revenue	\$	175,818	94,815	858,955	_	4,625,099	411,575	_	5,036,674
CARES Act grant revenue		24,016	21,678	82,618	_	520,451	50,206	_	570,657
Other revenue, net	_	1,184	6,136	13,581	(864,201)	248,190	306,850	(261,796)	293,244
Total revenue	_	201,018	122,629	955,154	(864,201)	5,393,740	768,631	(261,796)	5,900,575
Expenses:									
Salaries and wages		72,397	48,633	265,147	_	2,041,893	190,799	_	2,232,692
Physician fees and salaries		13,561	10,698	88,932	_	544,731	222,297	(166,657)	600,371
Employee benefits		11,478	8,678	55,194	(273,285)	414,281	56,175	(23,572)	446,884
Supplies		43,012	19,076	199,511	_	995,140	97,520	(6,041)	1,086,619
Other		50,283	30,042	239,481	(590,916)	936,858	195,354	(63,360)	1,068,852
Interest		4,355	531	18,737	_	100,196	3,173	(2,166)	101,203
Depreciation and amortization	_	9,260	4,722	34,412		244,176	13,294		257,470
Total expenses	_	204,346	122,380	901,414	(864,201)	5,277,275	778,612	(261,796)	5,794,091
Income (loss) from operations	_	(3,328)	249	53,740		116,465	(9,981)		106,484
Nonoperating revenue (expenses), net: Investment income (loss), net Other, net		(26)	4 (252)	50 (399)		793,721 1,722	5,086 (42)		798,807 1,680
Total nonoperating revenue (expenses), net		(26)	(248)	(349)		795,443	5,044		800,487
Excess (deficiency) of revenue over expenses		(3,354)	1	53,391		911,908	(4,937)		906,971
Pension changes other than net periodic benefit cost Net assets released from restriction for purchases of property and equipment Net assets transferred Other, net		 1,779	 76 1,547	4,585 — 1,692		(11,282) 18,107 9,668 (13,820)	(9,668) 15,815	 1,797	(11,282) 18,107 — 3,792
Total other changes in net assets		1,779	1,623	6,277		2,673	6,147	1,797	10,617
Increase (decrease) in net assets without donor restrictions		(1,575)	1,624	59,668	_	914,581	1,210	1,797	917,588
Change in net assets with donor restrictions Net assets, beginning of year		431 71,648	(21) 67,995	3,865 1,038,081	(125,000)	9,493 3,858,321	(6,395) 211,592	5,918 (137,089)	9,016 3,932,824
Net assets, end of year	\$	70,504	69,598	1,101,614	(125,000)	4,782,395	206,407	(129,374)	4,859,428